Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 1 Confidential   
  
 
 
A Phase 3 Study to Evaluate  the Immunogenicity and 
Safety  of Novavax  COVID -19 Vaccine(s)  as Second  or 
Subsequent Boosters After mRNA Vaccines in 
Individuals 18 to 49 Years of Age  
 
Investigational  Product(s)  NVX -CoV2373  and updated  Novavax  vaccine  based  on recent 
variant(s)  
Protocol  Number  2019nCoV -312 
Clinical  Trial  Registry  Identifiers  [STUDY_ID_REMOVED]  
Version  Number  2.1 
Version  Date  26 March  2025  
Amendment  1.1 
Sponsor  Novavax,  Inc. 
21 Firstfield  Road  
Gaithersburg,  MD 20878 
United States  
 
Confidentiality  Statement  
The information in this document is considered privileged and confidential by Novavax, Inc., 
and may not be disclosed  to others  except  to the extent  necessary  to obtain  Institutional  Review 
Board (IRB)  approval and informed consent, or as required by national and local laws. Persons 
to whom this information is disclosed must be informed that this information is privileged and 
confidential and that it should not be further disclosed.  
 
 
 
 
 
 

Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 2 Confidential   
 Statement  of Compliance  
The study will be conducted in compliance with this clinical study protocol, Good Clinical 
Practices  (GCP)  as outlined  by ICH E6(R2),  and all applicable  local  and national  regulatory 
requirements.  Enrollment at  any clinical  study  site may not begin  prior  to that site receiving 
approval from the ethics committee of record for the protocol and all materials provided to 
potential participants.  
Any amendments  to the protocol  or changes  to the consent  document  will be approved  before 
implementation of that amendment. Reconsent of previously enrolled participants may be 
necessary depending on the nature of the amendment.  
The Principal Investigator  will ensure  that changes to  the study  plan as defined  by this protocol 
will not be made  without  prior  agreement  from  the Sponsor  and documented  approval from  the 
ethics  committee  of record,  unless  such a change  is necessary  to eliminate  an immediate  hazard 
to the study participants.  
All personnel  involved  in the conduct  of this study  have  completed  Human  Subjects  Protection 
and GCP Training as outlined by their governing institution.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 4 Confidential   
 Investigator’s  Agreement  
I have  read the protocol,  appendices,  and accessory  materials  related  to Study  2019nCoV -312 
and agree to the following:  
• To conduct  this study  as described  by the protocol  and any accessory materials  
• To protect  the rights,  safety,  and welfare  of the participants  under  my care 
• To provide  oversight  to all personnel  to whom  study  activities  have  been delegated  
• To control  all investigational  products  provided  by the Sponsor  and maintain  records  of 
the disposition of those products  
• To conduct  the study  in accordance  with all applicable  local  and national  regulations,  the 
requirements of the ethics committee of record for my clinical site, and Good Clinical 
Practices as outlined by ICH E6(R2).  
• To obtain  approval  for the protocol  and all written  materials  provided  to participants  prior 
to initiating the study at my site  
• To obtain informed consent – and updated consent in the event of new information or 
amendments  – from  all participants  enrolled  at my study  site prior  to initiating  any study 
specific procedures or administering investigational products to those participants  
• To maintain  records  of each participant’s  participation  and all data required  by the 
protocol  
 
 
Name  Title  Institution  
   
Signature  Date  
  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 5 Confidential   
 Table  of Contents  
STATEMENT  OF COMPLIANCE  ................................ ................................ ...............................  2 
SPONSOR’S  APPROVAL  ................................ ................................ ................................ ............  3 
INVESTIGATOR’S  AGREEMENT  ................................ ................................ .............................  4 
TABLE  OF CONTENTS  ................................ ................................ ................................ ...............  5 
LIST  OF TABLES  ................................ ................................ ................................ .........................  9 
LIST  OF FIGURES  ................................ ................................ ................................ ........................  9 
LIST  OF APPENDICES  ................................ ................................ ................................ ................  9 
LIST  OF ABBREVIATIONS  ................................ ................................ ................................ ...... 10 
1 SYNOPSIS  ................................ ................................ ................................ .......................  12 
1.1 Schedule  of Events  ................................ ................................ ................................ ........  14 
2 INTRODUCTION  ................................ ................................ ................................ ............  17 
2.1 Background  ................................ ................................ ................................ ...................  17 
2.1.1 Description  of NVX -CoV2373  ................................ ................................ ..................  17 
2.1.2 Supportive  Nonclinical  Data ................................ ................................ ......................  18 
2.1.3 Supportive  Clinical  Data ................................ ................................ ............................  18 
2.1.3.1  Clinical  Pharmacology  and Safety  ................................ ................................ ..........  19 
2.1.4 Benefit:Risk  Assessment  ................................ ................................ ............................  20 
2.2 Study  Rationale  ................................ ................................ ................................ .............  20 
3 OBJECTIVES  AND  ENDPOINTS  ................................ ................................ ..................  22 
4 STUDY  PLAN  ................................ ................................ ................................ .................  25 
4.1 Study Schematic  ................................ ................................ ................................ ............  25 
4.2 Study Design  ................................ ................................ ................................ .................  25 
4.3 Design  Rationale  ................................ ................................ ................................ ...........  25 
5 POPULATION  ................................ ................................ ................................ .................  26 
5.1 Recruitment  ................................ ................................ ................................ ...................  26 
5.2 Definitions  ................................ ................................ ................................ .....................  26 
5.3 Inclusion  Criteria  ................................ ................................ ................................ ...........  26 
5.4 Exclusion  Criteria  ................................ ................................ ................................ ..........  27 
6 STUDY  CONDUCT  ................................ ................................ ................................ ........  28 
6.1 Study Procedures  ................................ ................................ ................................ ...........  28 
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 6 Confidential   
 6.1.1 Screening  Period  ................................ ................................ ................................ ........  28 
6.1.2 Vaccine  Administration  Period  (Day  1) ................................ ................................ ..... 28 
6.1.3 Day 8 Visit  ................................ ................................ ................................ .................  29 
6.1.4 Day 29 Visit  ................................ ................................ ................................ ...............  29 
6.1.5 Days  61, 91, 121 and  151 (Phone  Call)  ................................ ................................ ..... 30 
6.1.6 Day 181 (End  of Study  Phone  Call)  ................................ ................................ ...........  30 
6.1.7 Unscheduled  Visit  ................................ ................................ ................................ ...... 30 
6.2 Discontinuation  or Withdrawal  ................................ ................................ .....................  30 
6.2.1 Withdrawal  from  Study.  ................................ ................................ .............................  30 
6.2.1.1  Replacement  of Participants  ................................ ................................ ....................  31 
6.2.1.2  Participants  Lost to Follow -up ................................ ................................ ................  31 
6.2.1.3  Study  Vaccination  Pause  Rules  ................................ ................................ ...............  31 
6.3 Study  Termination  by Sponsor  ................................ ................................ ......................  31 
7 STUDY  INTERVENTIONS  ................................ ................................ ............................  32 
7.1 Description  of Products  ................................ ................................ ................................ . 32 
7.1.1 NVX -CoV2373  Ancestral  Strain  ................................ ................................ ...............  32 
7.1.1.1  Formulation,  Storage,  Preparation,  and Handling  ................................ ...................  32 
7.1.1.2  Packaging  and Labeling  ................................ ................................ ..........................  32 
7.1.1.3  Dosing  and Administration  ................................ ................................ .....................  32 
7.1.2 Updated  Novavax  COVID -19 Vaccine  Based  on Recent  Variant(s)  .........................  33 
7.1.2.1  Formulation,  Storage,  Preparation,  and Handling  ................................ ...................  33 
7.1.2.2  Packaging  and Labeling  ................................ ................................ ..........................  33 
7.1.2.3  Dosing  and Administration  ................................ ................................ .....................  33 
7.2 Treatment  Assignment  and Bias Minimization  ................................ .............................  33 
7.2.1 Treatment  Allocation  ................................ ................................ ................................ .. 33 
7.2.2 Assessment  and Verification  of Compliance  ................................ .............................  33 
7.3 Prior  and Concomitant  Therapies  ................................ ................................ ..................  33 
7.3.1 Prohibited  Therapies  ................................ ................................ ................................ .. 34 
8 SAFETY  ASSESSMENTS  ................................ ................................ ..............................  35 
8.1 Definitions  ................................ ................................ ................................ .....................  35 
8.1.1 Documenting  Adverse  Events  ................................ ................................ ....................  36 
8.1.2 Details  of the Adverse  Event  ................................ ................................ ......................  37 
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 7 Confidential   
 8.1.2.1  Assessment  of Causality  ................................ ................................ ..........................  37 
8.1.2.2  Action  Taken  with Study  Vaccine  due to Adverse Event  ................................ ....... 38 
8.1.2.3  Other  Action  Taken  ................................ ................................ ................................ . 38 
8.1.2.4  AE Outcome  ................................ ................................ ................................ ............  38 
8.1.3 Timeframe  for Collection  ................................ ................................ ...........................  38 
8.1.4 Classification  of Events  ................................ ................................ ..............................  39 
8.1.4.1  Treatment -Emergent  Adverse  Event  ................................ ................................ ....... 39 
8.1.4.2  Adverse  Events  of Special  Interest  ................................ ................................ ..........  39 
8.1.4.3  Medically  Attended  Adverse  Events  ................................ ................................ ....... 41 
8.1.4.4  Reactogenicity  Symptoms  ................................ ................................ .......................  42 
8.2 Reporting  Adverse  Events  ................................ ................................ .............................  42 
8.2.1.1  Safety Reporting to Health Authorities, Independent Ethics Committees/  
Institutional  Review  Boards,  and Investigators  ................................ .......................  43 
8.3 Pregnancy  ................................ ................................ ................................ ......................  43 
8.4 Overdose  ................................ ................................ ................................ .......................  44 
9 ANALYSIS  ................................ ................................ ................................ ......................  45 
9.1 Sample  Size Rationale  ................................ ................................ ................................ ... 45 
9.2 Analysis  Subsets  ................................ ................................ ................................ ............  45 
9.2.1 Selected  Participants  Analysis  Set ................................ ................................ .............  45 
9.2.2 Full Analysis  Set ................................ ................................ ................................ ........  46 
9.2.3 Safety  Analysis  Set................................ ................................ ................................ ..... 46 
9.2.4 Per-Protocol  Analysis  Set ................................ ................................ ...........................  46 
9.2.4.1  Anti-S Protein  IgG Serology  Subset  ................................ ................................ ....... 46 
9.2.4.2  Neutralization  Assay  Subset ................................ ................................ ....................  46 
9.2.4.3  hACE2  Receptor -Binding  Inhibition  Assay  Subset  ................................ ................  46 
9.3 Statistical  Analyses  ................................ ................................ ................................ ....... 46 
9.3.1 Background  Analyses  ................................ ................................ ................................ . 46 
9.3.1.1  Disposition  and Protocol  Compliance  ................................ ................................ ..... 46 
9.3.1.2  Demographics  and Baseline  Characteristics  ................................ ...........................  47 
9.3.2 Immunogenicity  Analyses  ................................ ................................ ..........................  47 
9.3.3 Safety  Analyses  ................................ ................................ ................................ ..........  49 
9.3.3.1  Prior  and Concomitant  Medications  and Vaccinations  ................................ ...........  50 
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 8 Confidential   
 9.3.3.2  Vital  Sign Measurements  ................................ ................................ ........................  50 
9.3.3.3  Physical  Examinations  ................................ ................................ ............................  50 
9.4 Interim  Analyses  ................................ ................................ ................................ ...........  50 
9.5 Final  Analysis  ................................ ................................ ................................ ................  50 
10 ETHICAL  CONSIDERATIONS  ................................ ................................ .....................  51 
10.1 Good  Clinical  Practice  ................................ ................................ ................................ .. 51 
10.2 Ethics  Review  ................................ ................................ ................................ ................  51 
10.3 Informed  Consent  ................................ ................................ ................................ ..........  51 
10.4 Data  Privacy  ................................ ................................ ................................ ..................  52 
11 OVERSIGHT  ................................ ................................ ................................ ...................  53 
11.1 Quality  Control  and Assurance  ................................ ................................ .....................  53 
11.1.1  Monitoring  ................................ ................................ ................................ ..................  53 
11.1.2  Audits  ................................ ................................ ................................ .........................  53 
11.1.3  Protocol  Deviations  ................................ ................................ ................................ .... 54 
11.1.4  Records  ................................ ................................ ................................ .......................  54 
11.1.4.1  Data  Capture  and Management  ................................ ................................ ...............  54 
11.1.4.2  Source  Documentation  ................................ ................................ ............................  54 
11.1.4.3  Records  Retention  ................................ ................................ ................................ ... 55 
11.2 Study  Termination  or Study  Site Closure  ................................ ................................ ..... 55 
12 PUBLICATION  POLICY  ................................ ................................ ................................  56 
13 FINANCING  AND  INSURANCE  ................................ ................................ ..................  57 
14 REFERENCES  ................................ ................................ ................................ .................  58 
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 9 Confidential   
 List of Tables  
Table  1 Schedule  of Events  ................................ ................................ ...............................  15 
Table  2 Study  2019nCoV -312 Objectives  and Endpoints  ................................ .................  22 
Table 3  Case Definitions of Probable and Confirmed Myocarditis, Pericarditis, and  
Myopericarditis  ................................ ................................ ................................ .... 40 
Table  4 Management  of Suspected  Myocarditis,  Pericarditis,  and Myopericarditis  
Cases ................................ ................................ ................................ .....................  41 
Table  5 Summary  of Sample  Size ................................ ................................ .....................  45 
Table  6 Potential  Immune -Mediated  Medical  Conditions  ................................ ................  61 
Table  7 Adverse  Events  Representing  Complications  Specific  to COVID -191 ........................  62 
Table 8  FDA  Toxicity  Grading  Scale  for Local  and General  Systemic  
Reactogenicity  ................................ ................................ ................................ ...... 63 
 
List of Figures  
Figure  1 Flow  Diagram  of Study  2019nCoV -312 ................................ ..............................  25 
 
List of Appendices  
Appendix  1 PROTOCOL  CHANGE  HISTORY  ................................ ................................ ..... 60 
Appendix  2 LISTINGS  OF ADVERSE  EVENTS  OF SPECIAL  INTEREST  .......................  61 
Appendix  3 TOXICITY  GRADING  SCALE  FOR  CLINICAL  ABNORMALITIES,  
(local  and general  systemic  reactogenicity,  clinical  laboratory,  and vital 
signs)  ................................ ................................ ................................ ....................  63 
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 10 Confidential   
 List of Abbreviations  
 
Abbreviation  Definition  
AE Adverse  event  
AESI  Adverse  event  of special  interest  
ANCA  Anti-neutrophil  cytoplasmic  antibody  
ANCOVA  Analysis  of covariance  
ARDS  Acute  respiratory  distress  syndrome  
ATC  Anatomical  therapeutic  chemical  
BAL  Bronchoalveolar  lavage  
BMI Body  mass  index  
CI Confidence  interval  
COVID -19 Coronavirus  disease  2019  
CRO  Clinical  research  organization  
DAIDS  Division  of AIDS  
ECG  Electrocardiogram  
eCRF  Electronic  case report  form 
EDC  Electronic  data capture  
ELISA  Enzyme -linked  immunosorbent  assay  
EOS End of Study  
ER Emergency  room  
FAS Full Analysis  Set 
FDA  United  States  Food  and Drug  Administration  
GCP  Good  Clinical  Practice  
GLP Good  Laboratory  Practice  
GMEU  Geometric  mean  ELISA  unit 
GMEUR  Between -group  ratio of IgG GMEUs  
GMFR  Geometric  mean  fold rise 
GMT  Geometric  mean  titer 
GMTR  Between -group  ratio of Nab GMTs  
GP Glycoprotein  
hACE2  Human  angiotensin -converting  enzyme  2 
IB Investigator’s  Brochure  
ICF Informed  consent  form 
ICH International  Council  for Harmonisation  of Technical  Requirements  for 
Pharmaceuticals for Human Use  
IgA Immunoglobulin  A 
IgG Immunoglobulin  G 
IM Intramuscular  
IND Investigational  New  Drug  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 11 Confidential   
  
Abbreviation  Definition  
IRB Institutional  Review  Board  
MAAE  Medically  attended  adverse  event  
MedDRA  Medical  Dictionary  for Regulatory  Activities  
MERS  Middle  East Respiratory  Syndrome  
MHC  Major  histocompatibility  complex  
Nab Neutralizing  antibody  
OTC  Over -the-counter  
PCR Polymerase  chain  reaction  
PIMMC  Potential  immune -mediated  medical  conditions  
PP Per-Protocol  
PT Preferred  term 
RNA  Ribonucleic  acid 
Rs Recombinant  spike  
S Spike  (protein)  
SAE Serious  adverse  event  
SAR  Serious  adverse  reaction  
SARS -CoV Severe  acute  respiratory  syndrome  coronavirus  
SARS -CoV-2 Severe  acute  respiratory  syndrome  coronavirus  2 
SCR Seroconversion  rate 
Sf9 Spodoptera  frugiperda  
SII Serum  Institute  of India  
SOC  System  organ  class 
SOE Schedule  of Events  
SUSAR  Suspected  unexpected  serious  adverse  reaction  
TEAE  Treatment -emergent  adverse  event  
US United  States  
WHO  World  Health  Organization  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 12 Confidential   
 1 Synopsis  
 
Title  A phase 3 study to evaluate the immunogenicity and safety of Novavax 
COVID -19 vaccine(s)  as second  or subsequent  booster  after mRNA  vaccines 
in individuals 18 to 49 years of age  
Short  Title  Phase  3 study  of Novavax  vaccine(s)  as booster  dose after mRNA  vaccines  
Phase  Phase  3 
Study  Design  This is an open -label  Phase  3 study  evaluating  the immunogenicity  and safety 
of Novavax vaccine(s) with Matrix -M™ adjuvant (ancestral strain  
NVX -CoV2373  and an alternative  strain  and/or  multivalent  Novavax  vaccine) 
as booster doses following a series of primary and booster doses of 
authorized/approved mRNA vaccines followed by a single booster dose of 
NVX -CoV2373 in the Novavax 2019nCoV -307 study (Study 307).  
This study  will enroll  up to 300 adult  participants  who previously  participated 
in Study 307.  Approximately 100 -150 participants will receive 1 dose of 
ancestral strain NVX -CoV2373 vaccine, given on Day 1, at a dose level of  
5 µg of ancestral strain antigen with 50 µg of Matrix -M adjuvant. 
Subsequently,  another  100-150 participants  may be enrolled  to receive  1 dose 
of an updated Novavax vaccine based on recent variant(s) at a dose level of  
5 µg total antigen  with 50 µg of Matrix -M adjuvant.  
All participants  will remain  on study  for assessment  of immunogenicity  at Day 
29 and safety data collection through 6 months (Day 181) following the 
vaccination.  
Target  Population  Medically stable male and non -pregnant female prior participants who 
received  their first booster  of NVX -CoV2373  in Study  307 following  prior 
priming and booster doses with mRNA vaccines.  
Number  of Participants  Total  number  of participants  planned:  Approximately  200 - 300; with 100 – 
150 to receive a single dose of NVX -CoV2373 ancestral strain COVID -19 
vaccine.  100-150 additional  participants  may be enrolled  to receive  a single 
dose of an updated  Novavax  COVID -19 vaccine  based  on recent  variant(s).  
Length  of Participation  On study  (including  screening  and follow -up): up to 7 months  
Intervention  Ancestral strain SARS -CoV -2 rS vaccine is supplied as a suspension for 
injection,  at a concentration  of 10 µg rS antigen  and 100 µg Matrix  M adjuvant 
per mL. If introduced to the study, the updated variant Novavax vaccine will  
be supplied and prepared as described in the Pharmacy Manual. The regimen 
for any final preparations  will comprise  1 intramuscular  (IM)  injection  (Day  1) 
of 0.5 mL injection volume with a total dose of 5 µg recombinant rS antigen 
with 50 µg Matrix M adjuvant. Vaccine will be administered as an open -label 
material.  
Primary  Objective  and 
Primary Endpoint  Hypothesis:  Neutralizing  antibody  (Nab)  responses  following  1 booster  dose of 
Novavax vaccine will be non-inferior to the increases observed in participants 
who received their first booster of Novavax vaccine in Study 307 following 
prior priming and booster doses with mRNA vaccines.  
Objective:  To characterize  the Nab responses  (geometric  mean  titers  [GMTs]) 
to ancestral strain Novavax vaccine administered as a second (or subsequent) 
booster after licensed mRNA vaccines and a first ancestral strain Novavax 
vaccine booster.  
Endpoints : 
• Nab GMTs  to the ancestral  strain  SARS -CoV -2 at Day 29. Non-inferiority 
will be demonstrated if the lower -bound (LB) of the 95% confidence  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 13 Confidential   
   
 intervals  (CIs)  for the ratio of Nab GMT  at Day 29 between  the two 
booster periods is > 0.67.  
• If non -inferiority is demonstrated, results will be tested for superiority, 
defined  as the LB of 95% CIs for the ratio of Nab GMT  at Day 29 > 1.0. 
Secondary  Objective(s)  and 
Corresponding  Endpoint(s)  Objective:  To further characterize the Nab responses (seroconversion rate 
[SCR]) to ancestral strain Novavax vaccine administered as a second (or 
subsequent)  booster  after licensed  mRNA  vaccines  and a first ancestral  strain 
Novavax vaccine booster.  
Endpoint:  
• Proportion  of participants  who achieve  seroconversion  (≥ 4-fold 
increase from baseline) in neutralization antibody titers to the 
SARS -CoV -2 at Day 29 compared with results of the same  
measurements in participants who received their first ancestral strain 
Novavax vaccine booster after mRNA vaccination in Study 307 in the 
same  participants.  Non-inferiority  will be demonstrated  if the LB of the 
95% exact CIs for the difference of SCRs in Nab titers is higher than – 
10% 
Objective:  To demonstrate the noninferior immunogenicity of Novavax 
vaccine  as a second  (or subsequent)  booster  vs as a first booster  of ancestral 
strain Novavax vaccine following mRNA vaccines.  
Endpoint:  
• Immunoglobulin G (IgG) geometric mean enzyme -linked 
immunoassay (ELISA) unit concentrations (GMEU/mL) to the 
SARS -CoV -2 ancestral  strain  spike  protein  at Day 29; non-inferiority 
will be demonstrated if the LB of the 95% CIs for the ratio of IgG 
GMEU at Day 29 between the two booster periods is > 0.67.  
• If non-inferiority  is demonstrated,  results  will be tested  for superiority, 
defined as a lower 95% CI of GMEU ratio > 1.0.  
• Proportion of participants who achieve seroconversion (≥ 4 -fold 
increase from baseline) in IgG concentrations to the SARS -CoV -2 
ancestral strain spike protein at Day 29 compared with results of the 
same measurements in participants who received their first ancestral 
strain Novavax vaccine boost er after mRNA vaccination in Study 307. 
Non-inferiority  will be demonstrated  if the LB of the 95% exact  CIs for 
the difference of SCRs in IgG ELISA unit is higher than –10%.  
Objective:  To characterize the cross -reaction of neutralizing and IgG 
antibodies  induced  by the ancestral  strain  Novavax  vaccine  to more  recent 
SARS -CoV -2 variants for which appropriate assays are available.  
Endpoint:  
• Post-booster  neutralizing  GMTs  and IgG GMEUs  compared  with 
post-first booster results from Study 307.  
Objective:  To further  characterize  antibody  responses  in a human  angiotensin - 
converting  enzyme  2 (hACE2)  receptor  binding  inhibition  assay  to the SARS - 
CoV -2 ancestral strain spike protein using the same calculations and 
comparison group for neutralizing and IgG antibodies. (second arm)  
Endpoint:  
• Seroresponse  data from  Study  307 participants  enrolled  to the second 
treatment group of this study to receive an updated Novavax vaccine 
based on recent variant will be assayed using the same assays as  
described above. hACE2 antibodies post -updated booster will be 
compared  to those  post-ancestral  strain  boosters  and will be analyzed  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 14 Confidential   
  
 
 in the same  manner  specifically  to assess  reactivity  with the ancestral 
strain virus/spike protein and with recent variant virus/spike protein.  
Objective:  To describe the overall safety of ancestral strain and updated (if 
administered)  Novavax  vaccine(s)  administered  as a second  (or subsequent) 
booster following licensed mRNA vaccines and a first ancestral strain 
Novavax vaccine booster.  
Endpoints:  
• Incidence,  duration,  and severity  of solicited  adverse  reactions  in the 
7 days following study vaccination.  
• Incidence, duration, severity, and relationship of medically attended 
adverse  events  (MAAEs)  and adverse  events  of special  interest  (AESIs), 
(including myocarditis and/or pericarditis) through Day 181 after the 
vaccine dose.  
• Incidence  and relationship  of serious  adverse  events  (SAEs)  through 
Day 181 after the vaccine dose. . 
Exploratory  Objective(s)  and 
Corresponding Endpoint(s)  Objective : To utilize  additional  assays  (current  or to be developed)  to best 
characterize the immune response for future vaccine development needs, 
including testing against emerging variants of SARS -CoV -2. 
Endpoint : Additional  endpoints  to evaluate  immune  responses  may be 
developed based on the assays used.  
Number  of Sites  Up to 20 sites in the US 
Study  Duration  Estimated  duration:  6 months  (excluding  screening)  
1.1 Schedule of Events  
The schedule  of events  (SOE)  is presented  in Table  1. 
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Table  1 Schedule of Events  
Novavax,  Inc. 15 Confidential   
  
 
 
Study  Day  
–30 to 11  
11  
8  
29 Unscheduled 
Visit   
61  
91  
121  
151  
181 
Window  (days)  -- − +3 + 4 -- ± 7 ± 15 ± 15 ± 15 + 15 
 
Study  Visit   
Screening   
1  
2  
3  Phone 
Call Phone 
Call Phone 
Call Phone 
Call EOS  
Phone  Call 
Informed  consent  X          
Medical  history2 X    X      
Inclusion/exclusion  criteria3 X X4         
Demographics  X          
Prior/concomitant  medications5 X X4 X X X X X X X X 
Vital  sign measurements  X X4   X      
Urine  pregnancy  test (WOCBP)  X X4         
Physical  examination6 X X4   X7      
Baseline  ECG   X4         
Nasal  swab  at clinic  for SARS -CoV -2 
(PCR) – anterior nares    
X4         
Blood  sample  for anti-NP testing   X4  X       
Blood sampling for SARS -CoV -2 
(ELISA  for anti S-protein  serology, 
neutralizing antibody titers, and 
hACE2 receptor -binding inhibition 
assay)    
 
 
X4   
 
X       
Vaccination   X8         
Reactogenicity  and diary  collection   X8,9 X9        
SAEs  X X X X X X X X X X 
All unsolicited  AEs  X X X X      
MAAEs and AESIs (including 
PIMMCs,  myocarditis  or pericarditis)   X10 X10 X10 X10,11  X11 X11 X11 X11 X11 
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Table  1 Schedule of Events  
Novavax,  Inc. 16 Confidential   
  
 
 
Study  Day  
–30 to 11  
11  
8  
29 Unscheduled 
Visit   
61  
91  
121  
151  
181 
Window  (days)  -- − +3 + 4 -- ± 7 ± 15 ± 15 ± 15 + 15 
 
Study  Visit   
Screening   
1  
2  
3  Phone 
Call Phone 
Call Phone 
Call Phone 
Call EOS  
Phone  Call 
EOS  form12          X 
Abbreviations:  AESI  = adverse  event(s)  of special  interest ; eCRF  = electonic  case report  form;  EDC  = electronic  data capture ; ELISA  = enzyme -linked  immunosorbent 
assay; EOS = end of study; hACE2 = human angiotensin -converting enzyme 2; MAAE = medically attended adverse event;  PCR = polymerase chain reaction; 
PIMMC = potential immune -mediated medical conditions;  S = spike (protein); SAE = serious adverse event; SARS -CoV -2 = severe acute respiratory syndrome 
coronavirus 2; WOCBP = women of childbearing potential.  
1. The Screening visit  and Day  1 visit  should be  combined  if feasible  at any given  study site. 
2. Significant  medical  history  should  be recorded,  focusing  on ongoing  medical  conditions.  
3. Specific  exclusions  to study  vaccination  will be assessed  before  vaccination.  Waivers  to enrolling  participants  with exclusions  will not be given.  
4. Performed  prior  to study  vaccination.  
5. Recent (≤ 90 days) and current medications, including non -COVID -19 vaccines, should be recorded in the concomitant medication electronic case report form (eCRF). All 
COVID -19 vaccines administered prior to Screening should be recorded in the vaccine history eCRF. Do no t record herbals, vitamins, and/or supplements. All assessments 
should  be performed  prior  to vaccination.  After  Day 29, record  all COVID -19 vaccines  and only record  concomitant  medications  and other  vaccines  that may have  caused  or 
are used to treat an AE. 
6. Examination  at Screening  to include  height  and weight;  cervical  and axillary  lymph  nodes,  heart  and any other  symptom -directed  (targeted)  examination.  
7 A targeted  physical  examination  should  be performed  as needed.  
8. On vaccination  day, participants  will remain in  the clinic  or under  study  staff observation for  at least 15 minutes  post-vaccination to  be monitored for  any immediate 
hypersensitivity reactions.  
9. Reactogenicity (solicited  adverse  events  related to vaccination)  will be recorded  by participants  via diary on  Days  1-7. The diary will  be collected from  the participant  at the 
Day 8  visit and will  be used to  populate  reactogenicity  data in EDC. Should any reactogenicity  event  extend  beyond 7  days after  vaccination (toxicity  grade  ≥1), then it  will 
be recorded as an AE with the same start date as the reactogenicity event and followed to resolution.  
10. All MAAEs  and all AESIs  (including potential  immune -mediated  medical  conditions  [PIMMCs]  and myocarditis  or pericarditis  will be recorded.  See Table  3 for symptoms 
of myocarditis or pericarditis and Table 4  for instructions for follow -up. 
11. MAAEs  attributed  to study  vaccine  and all AESIs  (including  PIMMCs  and myocarditis  or pericarditis)  will be recorded.  See Table  3 for symptoms  of myocarditis  or 
pericarditis and Table 4  for instructions for follow -up. 
12. EOS  form  will be completed  for all participants,  including  participants  who are terminated early.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 17 Confidential   
 2 Introduction  
2.1 Background  
Coronaviruses  are medium  sized,  enveloped,  positive -stranded  ribonucleic  acid (RNA)  viruses, 
with a characteristic crown -like appearance in electron micrographs due to circumferential 
studding of the viral envelope with projections comprising the spike (S) protein. There are  
4 different strains (229E, OC43, NL63, and HKU1), which are ubiquitous in humans and 
generally  result  in mild upper  respiratory  illnesses  and other  common  cold symptoms,  including 
malaise, headache, nasal discharge, sore throat, fever, and cough (Su 2016 ). 
In addition, other coronavirus strains are widespread in animals, where they typically cause 
enteric disease. These zoonotic coronaviruses have been known to evolve into strains that can 
infect humans with serious consequences, including severe acute respi ratory syndrome 
coronavirus  (SARS -CoV)  from  2002  to 2003,  Middle  East Respiratory  Syndrome  (MERS) -CoV 
since 2012, and most recently, the novel SARS -CoV -2 since 2019 (Habibzadeh 2020 ). 
In late December of 2019, an outbreak of respiratory disease caused by a novel coronavirus 
(2019nCoV) was detected in Wuhan, Hubei province, China. The virus’ rapidly discerned 
genetic relationship with the 2002 -2003 SARS -CoV has resulted in adoption of th e name 
“SARS -CoV -2,” with the disease being referred to as coronavirus disease 2019 (COVID -19). 
Nearly  two years  later,  SARS  CoV -2 transmission  remains  high,  partly  due to the emergence  of 
multiple variant strains of the virus. The World Health Organization (WHO) situation report 
from 09 February 2022 identified 399,600,607 confirmed cases and 5,757,562 deaths globally  
(WHO  2022 ). 
The present study aims to evaluate the immunogenicity and safety of Novavax COVID -19 
vaccine(s)  as second  or subsequent  booster  after mRNA  vaccines  in individuals  18 to 49 years  of 
age. 
2.1.1 Description  of NVX -CoV2373  
NVX -CoV2373 is the ancestral strain SARS -CoV -2 rS nanoparticle vaccine construct 
adjuvanted  with Matrix -M™ adjuvant  that is intended  to be used for the active  immunization  for 
the prevention of mild, moderate, and severe COVID -19 caused by SARS -CoV -2 in adults  
18 years  of age and older.  NVX -CoV2373  is constructed  from  the full-length,  wild-type 
SARS -CoV -2 S glycoprotein (GP) based on the GenBank gene sequence MN908947,  
nucleotides  21563 -25384  from  the 2019  SARS -CoV -2 genome.  The S protein  from  each virus  is 
a type 1 trimeric GP that is produced as an inactive S0 precursor. The S -gene was  
codon -optimized  for expression  in Spodoptera  frugiperda  (Sf9)  insect  cells.  
All SARS -CoV -2 rS vaccines are adjuvanted with Matrix -M adjuvant. Matrix -M is a saponin - 
based adjuvant, derived from the bark of the Quillaja saponaria Molina tree, which can be 
coadministered with an antigen to induce a targeted and enhanced immune response. The 
proposed  mode  of action  of Matrix -M adjuvant  does not include  a depot  effect,  but rather  occurs 
through a  combination of activities, including recruitment and activation of innate  immune  cells 
to the site of vaccine injection, rapid antigen delivery to antigen -presenting cells (APCs), and  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 18 Confidential   
 enhanced  antigen  presentation  via both major  histocompatibility  complex  (MHC)  I and MHC II 
molecules in the draining lymph nodes.  
The investigational  products  used in this study  are manufactured  by Serum  Institute  of India  (SII) 
through a partnership with Novavax.  
Additional product information including manufacturing details and supportive clinical and 
nonclinical  study  summaries  can be found  in the SARS -CoV -2 rS Investigator’s  Brochure  (IB) 
(Novavax 2022 ). 
2.1.2 Supportive  Nonclinical  Data  
Supportive nonclinical data are available through studies conducted using Novavax 
manufactured  SARS -Co- 2 rS products.  Pharmacological  properties  of the SII-produced  vaccines 
used in this study are expected to be equivalent to those produced by Novavax. Nonclinical 
safety, immunogenicity, and protective efficacy have now been confirmed in Phase 3 clinical 
trials. Nonclinical data can be found in the Investigator’s Broc hure.  
A good laboratory practice (GLP) -compliant developmental and reproductive toxicity study was 
completed  in Sprague -Dawley  rats. Females  were  immunized  with placebo,  5 µg of SARS -CoV - 
2 rS antigen with 10 µg of Matrix -M adjuvant, or 10 µg of Matrix -M adjuvant alone. These 
doses were approximately 40 -fold in excess of the human dose, on a weight -adjusted basis, in a 
50 kg human female. Doses were given on pre -mating Days 1 and 15, and then, after mating, at 
gestational Days 7 and 15. Dams immunized with antigen plus adjuvant, but not adjuvant alone, 
had strong anti -S IgG responses, and vaccine -induced antibody was transferred transplacentally 
to the fetuses. Mating and fertility , as well as the number and viability of fetuses, were 
unaffected by adjuvant or complete vaccine. There was no treatment effect on fetal 
malformations or skeletal abnormalities. In dams allowed to deliver, receipt of adjuvant or 
complete vaccine did not a ffect the gestational duration at delivery or the number of live pups; 
and there was also no impact of the attainment of developmental milestones by pups through  
21 days of life. 
2.1.3 Supportive  Clinical  Data  
Supportive clinical data are available via studies conducted using Novavax manufactured 
SARS -CoV -2 rS products.  The clinical  development  program  for Novavax’s  SARS -CoV -2 rS 
with Matrix -M adjuvant  comprises  4 clinical  studies:  a Phase  1-2 study  of SARS -CoV -2 rS with 
or without Matrix -M adjuvant in healthy adult participants 18 to 59 years of age (Study 
2019nCoV -101– Part 1) and SARS -CoV -2 rS with Matrix -M adjuvant in healthy adult 
participants  18 to 84 years  of age (Study  2019nCoV -101 – Part 2); a Phase 2a/b  study  of SARS - 
CoV -2 rS with Matrix -M adjuvant in healthy adult participants 18 to 84 years of age living 
without human immunodeficiency virus (HIV) and medically stable adult participants 18 to 64 
years of age living with HIV (Study 2019nCoV -501); and 2 Phase 3 studies in healthy and 
medicall y stable  adult  participants  ≥ 18 years  of age and adolescent  participants  12 to < 18 years 
of age (Study 2019nCoV -301) and 18 to 84 years of age (Study 2019nCoV -302). Additionally, 
Study 2019nCoV -307 (Study 307), which looked at the effect of homologous an d heterologous 
boosting with NVX -CoV2373 in adults ≥18 years of age, formed the basis for this study and its  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 19 Confidential   
 enrollment  population.  Clinical  data from  Phase  1-2 trials  and additional  clinical  data from  Phase 
3 trials can be found in the Investigator’s Brochure.  
2.1.3.1  Clinical  Pharmacology  and Safety  
Study  2019nCoV -302 was a Phase  3, randomized  (1:1),  observer -blinded,  placebo -controlled 
trial evaluating the efficacy, safety, and immunogenicity of 5 µg SARS -CoV -2 rS with  
50 µg Matrix M - adjuvant, administered 21 days apart on Days 0 and 21 as a coformulation, in 
15,139 healthy and medically stable (with comorbidities) participants 18 to 84 years of age 
conducted in the UK. After the initial vaccination period, participants remained blinde d and 
crossed  over to the opposite  treatment  arm. An analysis  of the primary  efficacy  endpoint,  which 
included both immunogenicity and safety data, was performed. A total of 106 cases of  
PCR -confirmed symptomatic mild, moderate, or severe COVID -19 were accrued for the final 
prespecified  analysis  of the primary  endpoint,  with 10 (0.1%)  in the NVX -CoV2373  group  and 
96 (1.4%) in the placebo group. All but 5 cases were mild or moderate in severity, with all  
5 severe  cases  occurring  in the placebo  group.  The resultant  vaccine  efficacy  of NVX -CoV2373 
to prevent symptomatic mild, moderate, or severe COVID -19 in baseline seronegative (to  
SARS -CoV -2) adult  participants  was 89.7%  (95% CI:  80.2,  94.6;  p < 0.001),  with a lower  bound 
confidence interval (LBCI) > 30% meeting the prespecified study success criterion. PCR results 
of the final analysis by SARS -CoV -2 strain showed vaccine efficacy of 86.3% (95% CI: 71.3, 
93.5) for the B.1.1.7 (Alpha) variant and 96.4% (95% CI: 73.8, 9 9.5) for the ancestral (Wuhan) 
strain. NVX -CoV2373 induced robust immune responses (anti -S IgG and neutralizing antibody 
[Nab]),  which  were  1.3-fold (anti-S IgG)  and 1.4-fold (Nab)  higher  in the younger  age cohort  (18 
to 64 years) than in the older age cohort (65 to 84 years), but seroconversion rates (SCRs) were  
at least 98% in both age cohorts. NVX -CoV2373 was well tolerated, with similar frequencies of 
SAEs,  MAAEs,  and AESIs compared  to placebo. Solicited  local  and systemic  reactogenicity  in a 
subset of 2,714 participants were higher for NVX -CoV2373 than placebo, but the majority of 
reported events were classified as grade 1 following first vaccination and grade 1 or grade 2 
following second vaccination. The most frequent local AEs following e ach vaccination were 
tenderness and pa in, with relatively short median durations following first (≤ 2.0 days) and 
second (≤ 3.0 days) vaccination. The most frequent solicited systemic AEs following each 
vaccination were headache, fatigue, and muscle pain, with relatively short median durations  
following first (≤ 1.5 days) and second (≤ 2.0 days) vaccination. Across the 2 age strata, 
participants in the older age cohort (65 to 84 years of age) reported a lower frequency and 
intensity of solicited local and systemic treatment emergent adverse eve nts (TEAEs) than 
participants in the younger age cohort (18 to 64 years of age).  
Study  2019nCoV -301 is a Phase  3, randomized  (2:1),  observer -blinded,  placebo -controlled  trial 
with a pediatric expansion evaluating the efficacy, safety, and immunogenicity of NVX - 
CoV2373, administered 21 days apart on Days 0 and 21 as a coformulation, in 29,582 healthy 
and medically stable (with comorbidities or at high risk for COVID -19) a dult participants 18 
years of age and older conducted in the United States (US) and Mexico and the safety and 
immunogenicity of NVX -CoV2373 in 2,247 healthy adolescent participants 12 to < 18 years of 
age conducted in the  US. In adults, final analysis of  the primary efficacy endpoint yielded a  VE 
of 90.41% (95% CI: 83.81, 94.32) for all participants. In addition, NVX -CoV2373 induced 
robust  immune  responses  and safety  data reflected  an acceptable  safety  profile.  These  data were  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 20 Confidential   
 submitted  to the FDA  in support  of a request  for Emergency  Use Authorization.  Subsequently, 
safety and immunogenicity data following a booster dose of NVX -CoV2373 from this study 
supported Emergency Use Authorization of the vaccine as a booster dose.  
Study 307 is a phase 3 study that compared the immunogenicity and safety of 3 lots of NVX - 
CoV2373 in adults to demonstrate the consistency of effect among the 3 manufacturing lots of 
drug product.  We also explored  the immunogenicity  of heterologous  and homologous  boosting 
on Wuhan and Omicron strains of COVID -19. NVX -CoV2373 showed equivalent 
immunogenicity across manufacturing lots, as measured by IgG and NAb responses. No new 
safety signals were identified. NVX -CoV2373 was also immunogenic regardless of whether it 
was used as a first booster or later booster dose, and whether it followed earlier doses of  
NVX -CoV2373  or other  authorized  vaccines.  Additionally,  it displayed  immunogenicity  against 
all 3 tested  variants  of SARS -CoV -2 rS. Participants  in Study  307 who received  a primary  series 
of an mRNA vaccine were invited to participate in this study.  
2.1.4 Benefit:Risk  Assessment  
Novavax has collected safety, efficacy, and immunogenicity data from approximately 
50,000  participants  across  5 clinical  trials,  including  2 independent  Phase  3 trials  in the 
US/Mexico (Study 2019nCoV -301) and the UK (Study 2019nCoV -302). The data from these 
trials,  along  with supporting  preclinical  studies,  indicate  that the known  and potential  benefits  of 
the vaccine outweigh its known and potential risks.  
Myocarditis or pericarditis has been reported following vaccination with NVX -CoV2373 in 
clinical trials, and it is possible that these reports represent vaccine -associated adverse events 
similar to those associated with mRNA COVID -19 vaccines. While availa ble data may not be 
sufficient  to definitively  establish  a causal  relationship  with NVX -CoV2373,  neither  can a causal 
relationship be excluded.  
Myocarditis or pericarditis associated with mRNA vaccines has been reported in greatest 
numbers in males under the age of 30 years following a second dose, but cases have been 
reported in older males and in females, and also following the first dose. While some cases 
require intensive care support, available data from short -term follow -up suggest that most 
individuals  have  had resolution  of symptoms  with conservative  management.  Information  is not 
yet available about potential long -term sequelae.  
The CDC has published clinical considerations for  myocarditis and pericarditis after  receipt of 
mRNA COVID -19 vaccines among adolescents and young adults [CDC 2021 ] which makes 
specific recommendations for the management of such cases. A surveillance and management 
plan for suspected myocarditis and/or pericarditis cases based on CDC and AHA 
recommendations  [CDC  2021 , Law 2021,  Gargano  2021 ] has been  implemented  in the clinical 
development plan of NVX -CoV2373.  
2.2 Study  Rationale  
Novavax, Inc. has developed a recombinant spike protein vaccine adjuvanted with the 
saponin -based  Matrix  M adjuvant  for the prevention  of disease  caused  by SARS -CoV -2 
(NVX -CoV2373).  Both  nonclinical  and clinical  data support  continued  clinical  development  of 
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 21 Confidential   
 SARS -CoV -2 recombinant  spike  protein  nanoparticle  vaccines  (SARS -CoV -2 rS) combined  with 
Matrix -M adjuvant as potential vaccines against SARS -CoV -2. 
The purpose  of this study  is to assess  safety  and immunogenicity  of ancestral  strain  
NVX -CoV2373  and, possibly,  an updated  Novavax  vaccine  based  on recent  variant(s),  when 
used as a second  booster  dose in individuals  who have  previously  received  a primary  vaccine 
series of licensed mRNA with or without a subsequent mRNA booster dose followed by one 
booster with ancestral strain NVX -CoV2373 vaccine in Study 307.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 22 Confidential   
 3 Objectives  and Endpoints  
The purpose of this study is to evaluate the immunogenicity and safety of Novavax COVID -19 
vaccine(s)  as second  or subsequent  booster  after mRNA  vaccines  in individuals  who were  18 to 
49 years of age (inclusive) at the time of vaccination in Study 307.  
An overview  of all study  objectives  and endpoints is  provided  in Table  2. 
Table  2 Study  2019nCoV -312 Objectives  and Endpoints  
 
 Objectives  Endpoints  
Primary  To characterize  the Nab responses 
(geometric  mean  titers  [GMTs])  to 
ancestral strain Novavax vaccine 
administered as a second (or 
subsequent) booster after licensed 
mRNA vaccines and a first 
ancestral strain Novavax vaccine 
booster.  • Nab GMTs to the ancestral 
strain SARS -CoV -2 at Day 29. 
Non-inferiority will be 
demonstrated if the lower - 
bound (LB) of the 95% CIs for 
the ratio of Nab GMT  at Day 29 
between the two booster  
periods is > 0.67.  
• If non -inferiority is 
demonstrated, results will be 
tested  for superiority,  defined  as 
the LB of 95% CIs for the ratio 
of Nab GMT at Day 29 > 1.0.  
Secondary  To further characterize the Nab 
responses (seroconversion rate 
[SCR]) to ancestral strain Novavax 
vaccine administered as a second 
(or subsequent) booster after 
licensed  mRNA  vaccines  and a first 
ancestral strain Novavax vaccine 
booster.  
. Proportion of participants who 
achieve seroconversion (≥ 4 -fold 
increase from baseline) in 
neutralization  antibody  titers  to the 
SARS -CoV -2 at Day 29 compared 
with results of the same 
measurements in participants who 
received their first ancestral strain 
Novavax vaccine booster after 
mRNA vaccination in Study 307. 
Non-inferiority will be 
demonstrated  if the LB of the 95% 
exact CIs for the difference of 
SCRs  in Nab titers  is higher  than – 
10% 
 To demonstrate the noninferior 
immunogenicity of Novavax 
vaccine  as a second  (or subsequent) 
booster vs as a first booster of 
ancestral strain Novavax vaccine 
boost following mRNA vaccines.  • IgG geometric mean enzyme - 
linked immunoassay (ELISA) 
unit concentrations  (GMEU/mL) 
to the SARS -CoV -2 ancestral 
strain spike protein at Day 29; 
Non-inferiority will be 
demonstrated  if the lower -bound 
(LB)  of the 95% CIs for the ratio 
of IgG GMEU at Day 29 
between the two booster periods 
is > 0.67.  
• If non -inferiority is 
demonstrated,  results  will be 
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Table  2 Study  2019nCoV -312 Objectives  and Endpoints  
Novavax,  Inc. 23 Confidential   
  
 
 Objectives  Endpoints  
  tested  for superiority,  defined  as 
a lower  95% confidence  interval 
of GMEU ratio >1.0.  
• Proportion of participants who 
achieve  seroconversion  (≥ 4-fold 
increase from baseline) in IgG 
concentrations to the SARS - 
CoV -2 ancestral strain spike 
protein  at Day 29 compared  with 
results of the same 
measurements in participants 
who received  their first ancestral 
strain Novavax vaccine booster 
after mRNA vaccination in 
Study 307. Non -inferiority will 
be demonstrated if the  LB of the 
95% exact  CIs for the  difference 
of SCRs in IgG ELISA unit is 
higher than –10%.  
 To characterize the cross -reaction 
of neutralizing and IgG antibodies 
induced by the ancestral strain 
Novavax vaccine to more recent 
SARS -CoV -2 variants and any 
other  variants  for which  appropriate 
assays are available.  Post-booster neutralizing GMTs  
and IgG GMEUs compared with 
post-first booster  results  from  Study 
307. 
 To further characterize antibody 
responses in a human angiotensin - 
converting enzyme 2 (hACE2) 
receptor  binding  inhibition  assay  to 
the SARS -CoV -2 ancestral strain 
spike protein using the same 
calculations and comparison group 
as noted  above  for neutralizing  and 
IgG antibodies.  Seroresponse data from Study 307 
participants enrolled to the second 
treatment group of this study to 
receive an updated Novavax 
vaccine  based  on recent  variant  will 
be assayed  using  the same  assays  as 
described  above.  hACE2  antibodies 
post-updated booster will be 
compared to those post -ancestral 
strain  boosters  and will be analyzed 
in the same manner specifically to 
assess reactivity with the ancestral 
strain virus/spike protein and with 
recent variant virus/spike protein.  
 To describe the overall safety of 
ancestral strain and updated (if 
administered) Novavax vaccine(s) 
administered as a second (or 
subsequent) booster following 
licensed  mRNA  vaccines  and a first 
ancestral strain Novavax vaccine 
booster.  • Incidence, duration, and 
severity of solicited adverse 
reactions in the 7 days 
following  study  vaccination.  
• Incidence,  duration,  severity, 
and relationship  of medically 
attended adverse events  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Table  2 Study  2019nCoV -312 Objectives  and Endpoints  
Novavax,  Inc. 24 Confidential   
  
 
 Objectives  Endpoints  
  (MAAEs)  and adverse  events  of 
special interest (AESIs), 
(including myocarditis and/or 
pericarditis) through Day 180 
after the vaccine dose.  
• Incidence and relationship of 
serious  adverse  events  (SAEs) 
through Day 180 after the 
vaccine dose.  
Exploratory  To utilize  additional  assays  (current 
or to be developed) to best 
characterize the immune response 
for future vaccine development 
needs, including testing against 
emerging  variants  of SARS -CoV -2. Additional endpoints to evaluate 
immune responses may be 
developed  based  on the assays  used.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 25 Confidential   
 4 Study  Plan  
4.1 Study  Schematic  
Figure  1 Flow  Diagram  of Study  2019nCoV -312 
Participants:  n=100  to 150 each  
NVX -CoV2373 ancestral strain (Arm 1) or Variant 
Strain (Arm 2)*  
Phone  Call 
 
 
 
Screening  and Day 1 
may be combined if  
feasible  
 
Up to 7 months  total duration  
Vaccine  Dose  5 µg antigen  + 50 µg Matrix  M adjuvant  ancestral  strain  or variant  strain  
*Arm  2 (optional)  will begin  after the start of  Arm 1 
 
4.2 Study  Design  
This is a Phase 3 study assessing the immunogenicity and safety of Novavax vaccine with 
Matrix -M adjuvant (NVX -CoV2373) as a booster dose following primary vaccination with 
authorized/approved mRNA vaccines (with or without subsequent mRNA booster) and one 
booster  dose of NVX -Co2373.  The study  will enroll  up to 300 previously  vaccinated  and boosted 
adults 18 to 49 years (inclusive) of age at the time of vaccination in Study 307.  
Participants  will be recruited  from  individuals  who previously  participated  in Study  307 
(received mRNA vaccine priming with or without a subsequent mRNA booster and an 
NVX - CoV2373 booster dose in Study 307).  
Participants  will receive  1 dose of study  vaccine, given  on Day 1, at a dose level  of 5 µg of rS 
antigen with 50 µg of Matrix -M adjuvant.  
All participants  will remain  on study  for immunogenicity  at Day 29 and safety  data collection 
through 180 days following the vaccination.  
4.3 Design  Rationale  
The purpose  of this study  is to assess  safety  and immunogenicity  of ancestral  strain  
NVX - CoV2373 and an updated Novavax vaccine based on recent variant(s), if administered, 
when  used as a second  booster  dose in individuals  who have  previously  received  primary  vaccine 
series with or without a booster dose of licensed mRNA vaccines followed by one booster with 
ancestral strain NVX -CoV2373 vaccine.   
 
EOS  Day 
181 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Day 91 
 
 
Day 61 
 
 
Day 151 
 
 
Day 121 
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 26 Confidential   
 5 Population  
5.1 Recruitment  
Qualified participants from Study 307 who received 2 or 3 doses of an mRNA vaccine prior to 
Study  307 then one dose of ancestral  strain  NVX -CoV2373  during  Study  307 will be screened  in 
order to enroll up to 300 participants. These participants may be enrolled in 2 groups of 100 to 
150 participants each, the first to receive the ancestral strain vaccine and the second, if enrolled, 
to receive an alternate vaccine based on a more recent  variant of the SARS -CoV -2 virus.  
Participants will be enrolled to the 2 groups in a non -randomized fashion; the alternative 
treatment  group,  if initiated,  will be conducted  in staggered  fashion  after enrollment  in the 
ancestral strain group has begun.  
5.2 Definitions  
Participants  officially  enter  the Screening  Period  following  provision  of informed  consent.  
A screen  failure  is a consented  participant  who has been  deemed  ineligible  on the basis  of one or 
more eligibility criteria or who has withdrawn consent prior to treatment assignment. Screen 
failures may not be rescreened.  
An enrolled  participant  is one who has been  deemed  eligible  and has been  assigned  to a 
treatment group.  
5.3 Inclusion  Criteria  
To be included  in this study,  each individual  must  satisfy  all the following  criteria:  
1. Adults 18 to 49 years (inclusive) of age at the time of vaccination in Study 307 who 
received  two or three  doses  of mRNA  prior  to enrollment  in Study  307, then one dose of 
ancestral strain NVX -CoV2373 in Study 307.  
2. Willing  and able to give informed  consent  prior  to study  enrollment  and to comply  with 
study procedures.  
3. Participants of childbearing potential (defined as any participant who has experienced 
menarche  and who is NOT  surgically sterile  [ie, hysterectomy, bilateral tubal ligation, or 
bilateral oophorectomy] or postmenopausal [defined as amenorrhea at least 12 
consecutive  months])  must  agree  to be heterosexually  inactive  from  at least 28 days prior 
to enrollment and through the end of study (EOS) visit OR agree to consistently use a 
medically acceptable method of contraception from at least 28 days prior to enrollment 
and through the EOS visit.  
4. Is medically  stable,  as determined  by the investigator  (based  on review  of health  status, 
vital signs  [to include  body  temperature],  medical  history,  and physical  examination  [to 
include body weight]). Vital signs must be within medically acceptable ranges prior to 
the study vaccination.  
5. Agree  to not participate  in any other  SARS -CoV -2 prevention  or treatment  trials  for the 
duration  of the study.  Note:  For participants  who become  hospitalized  with COVID -19, 
participation in investigational treatment studies is permitted.  
6. Documented  receipt  of COVID -19 vaccines.  The most  recent  dose of NVX -CoV2373 
must have been administered at least 180 days prior to vaccination in this study.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 27 Confidential   
 5.4 Exclusion  Criteria  
Participants  meeting  any of  the following  criteria will  be excluded  from  the study.  
1. Received  any additional  COVID -19 vaccine  booster  after the Day 1 dose of 
NVX -CoV2373 administered during participation in Study 307.  
2. History  of laboratory -confirmed  (by polymerase  chain  reaction  [PCR]  or rapid  antigen 
test) COVID -19 infection ≤ 4 months prior to Day 1.  
3. Current  participation  in research  involving  receipt  of an investigational  product 
(drug/biologic/device).  
4. Any known  allergies  or history  of anaphylaxis  to the active  substance  or any of the other 
ingredients contained in the investigational product.  
5. Any autoimmune  or immunodeficiency  disease/condition  (iatrogenic  or congenital)  or 
therapy that causes clinically significant immunosuppression.  
6. Received  any vaccine  ≤ 90 days prior  to study  vaccination,  except  for influenza  vaccine 
which  may be received  > 4 days prior  to study  vaccine,  or rabies  vaccine,  which  may be 
received at any time if medically indicated.  
7. Received immunoglobulin, blood -derived products, or immunosuppressant drugs within 
90 days prior  to study  vaccination,  except  for rabies  immunoglobulin  which  may be given 
if medically indicated.  
8. Active cancer (malignancy) on chemotherapy that is judged to cause significant 
immunocompromise  within  1 year prior  to first study  vaccination  (with  the exception  of 
malignancy cured via excision, at the discretion of the investigator).  
9. Participants  who are breastfeeding,  pregnant,  or who plan to become  pregnant  prior  to the 
EOS visit.  
10. Suspected  or known  history  of alcohol  abuse  or drug addiction  within  3 months  prior  to 
the study vaccine dose that, in the opinion of the investigator, might interfere with 
protocol compliance.  
11. Any other  condition  that, in the opinion  of the investigator,  would  pose a health  risk to 
the participant if enrolled or could interfere with evaluation of the trial vaccine or 
interpretation of study results (including neurologic or psychiatric conditions likely to 
impair the quality of safety reporting).  
12. Study team member or immediate family member of any study team member (inclusive  
of Sponsor,  clinical  research  organization  [CRO],  and study  site personnel  involved  in the 
conduct or planning of the study).  
13. Participants  with a history  of myocarditis  or pericarditis.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 28 Confidential   
 6 Study  Conduct  
This is a Phase 3 study comparing the immunogenicity and safety of Novavax vaccine(s) with 
Matrix -M adjuvant  (ancestral  strain  NVX -CoV2373  and an alternative  strain  and/or  multivalent 
Novavax vaccine) as booster doses following a series of primary and booster doses of 
authorized/approved mRNA vaccines followed by a single booster dose of NVX -CoV2373 in 
Study 307.  
Following  vaccination,  all participants  will remain  on study  for immunogenicity  on Day 29 and 
safety data collection through Day 181 (EOS).  
6.1 Study  Procedures  
6.1.1 Screening  Period  
The following  activities  will occur  at the Screening  Visit.  The Screening  Visit  may occur  up to 
30 days prior to Day 1, but can be and is expected to be combined with the Day 1 Visit when 
possible.  
• Informed  consent  
• Medical history, including prior and concurrent medical conditions and significant 
surgical  procedures  in the 6 months  prior  to enrollment.  Significant  medical  history 
should be recorded, focusing on ongoing medical conditions.  
• Inclusion  and exclusion  criteria  
• Demographics  including age,  sex, race,  and ethnicity.  
• Prior  and concomitant  medications,  including  recent  (≤ 90 days)  and current  medications 
and vaccinations, are to be reviewed to ensure eligibility criteria are fulfilled. All 
COVID -19 vaccines must be recorded, including type and dates of receipt. Concomitant 
medications include prescription and over -the-counter (OTC; including va ccines) 
medications taken by the participant during the study. Do not record herbals, vitamins, 
and/or supplements.  
• Vital  sign measurements,  including  respiratory  rate, blood  pressure,  pulse  rate, and 
temperature (oral or via forehead/ear reader).  
• Urine  pregnancy  test in women  of childbearing  potential  (WOCBP).  A positive  test will 
result in screen failure.  
• Physical  examination  at screening  to include  height  and weight,  cervical  and axillary 
lymph nodes, heart, and any other symptom -directed (targeted) examination.  
• Recording  of SAEs  following  signing  of informed  consent.  
6.1.2 Vaccine  Administration  Period  (Day  1) 
The following  activities  will occur  at the Day 1 visit.  
• Inclusion  and exclusion  criteria  
• Prior/concomitant  medications  
• Vital  sign measurements,  including  respiratory  rate, blood  pressure,  pulse  rate, and 
temperature (oral or via forehead/ear reader). Temperature will be taken prior to 
vaccination to ensure participant has no evidence of fever.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 29 Confidential   
 • Urine  pregnancy  test in WOCBP.  A positive  test will result  in disqualification.  
• Baseline  electrocardiogram  (ECG)  
• Physical  examination,  to include  cervical  and axillary  lymph  nodes,  heart,  and any other 
symptom -directed (targeted) examination.  
• Nasal  swab at  clinic  for SARS -CoV -2 (PCR) —anterior  nares  
• Blood  sampling  for anti-NP testing  
• Blood  sampling  for SARS -CoV -2 (ELISA  for anti-S protein  serology,  Nab titers,  and 
hACE2 receptor -binding inhibition assay)  
• Vaccination  
• Distribution  of the diary  to the participants,  including  a review  of how to complete  the 
diary with the participant  
• Recording of solicited (reactogenicity) and unsolicited AEs, SAEs, MAAEs, and AESIs 
(including  potential  immune -mediated  medical  conditions  [PIMMCs]  and myocarditis  or 
pericarditis). See Table 3  for symptoms of myocarditis or pericarditis and Table 4  for 
instructions for follow -up. 
• Participants  will remain  in the clinic  or under  study  staff observation  for at least 
15 minutes  post-vaccination  to be monitored  for any immediate  hypersensitivity 
reactions.  
6.1.3 Day 8 Visit  
The following  activities  will occur  at the Day 8 visit:  
• The diary  that participants  use to record  reactogenicity  data between  Days  1 and 7 will be 
reviewed with the participants and collected so that site personnel can record the 
information by electronic data capture (EDC).  
• Recording of unsolicited AEs, SAEs, MAAEs, and AESIs (including PIMMCs and 
myocarditis  or pericarditis).  See Table  3 for symptoms  of myocarditis  or pericarditis  and 
Table 4  for instructions for follow -up. 
NOTE: Should any reactogenicity event extend beyond 7 days after vaccination (toxicity 
grade  ≥ 1), then it will be recorded  as an AE with the same  start date as the reactogenicity 
event and followed to resolution.  
6.1.4 Day 29 Visit  
The following  activities  will occur  at the Day 29 visit.  
• Prior/concomitant  medications  
• Blood  sampling  for SARS -CoV -2 (ELISA  for anti-S protein  serology,  Nab titers,  and 
hACE2 receptor -binding inhibition assay)  
• Blood  sampling  for anti-NP testing  
• Recording of unsolicited AEs, SAEs, MAAEs, and AESIs (including PIMMCs and 
myocarditis  or pericarditis).  See Table  3 for symptoms  of myocarditis  or pericarditis  and 
Table 4  for instructions for follow -up. 
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 30 Confidential   
 6.1.5 Days  61, 91, 121 and 151  (Phone  Call)  
Participants  will receive a  phone  call and the following  information  will be collected:  
• Prior/concomitant  medications  or vaccines  that may have  caused  or are used to treat an 
AE. All COVID -19 vaccines received during the study should be recorded.  
• Recording  of SAEs,  MAAEs  attributed  to study  vaccine,  and AESIs  (including  PIMMCs, 
myocarditis or pericarditis). See Table 3  for symptoms of myocarditis or pericarditis and 
Table 4  for instructions for follow -up. 
6.1.6 Day 181 (End  of Study  Phone  Call)  
The following  activities  will be performed  at the EOS  Phone  Call.  . 
• Prior/concomitant  medications  or vaccines  that may have  caused  or are used to treat an 
AE. 
• Recording  of SAEs,  MAAEs  attributed  to study  vaccine,  and AESIs  (including  PIMMCs, 
myocarditis or pericarditis). See Table 3  for symptoms of myocarditis or pericarditis and 
Table 4  for instructions for follow -up. 
• Completion  of EOS  form 
6.1.7 Unscheduled  Visit  
An Unscheduled Visit may be conducted by study personnel for safety follow up for any 
participant  experiencing  a general  medical  issue  while  on study.  During  the visit,  the following 
procedures will be performed:  
• Prior/concomitant  medications  or vaccines  that may have  caused  or are used to treat an 
AE. 
• Vital  signs  measurement  including  respiratory  rate, blood  pressure,  pulse  rate, and 
temperature (oral or via forehead/ear reader)  
• Physical  examination  – symptom  directed  (targeted)  
• Recording of SAEs, AE/MAAEs, and AESIs (including PIMMCs, myocarditis or 
pericarditis)  per reporting  timelines  outlined  in Table  1. See Table  3 for symptoms  of 
myocarditis or pericarditis and Table 4  for instructions for follow -up. 
6.2 Discontinuation  or Withdrawal  
6.2.1 Withdrawal  from  Study  
Participants are free to withdraw from the study at any time upon request. Participant 
participation  in the study  may be stopped  at any time at the discretion  of the Investigator  or at the 
request of the Sponsor.  
Participants may refuse further procedures but are encouraged to remain in the study in order to 
collect a blood sample at Day 29 and to conduct safety follow -up through Day 181. In cases 
where  the participant  is not able to visit the study  site for the Day 29 visit,  participant  contact  for 
safety follow -up may be managed via telemedicine contact (eg, telephone, web chat, video, 
FaceTime).  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 31 Confidential   
 6.2.1.1  Replacement  of Participants  
Participants  who withdraw,  are withdrawn  or terminated  from  this study,  or are lost to follow  up 
after signing the informed consent form (ICF) but prior to study vaccination may be replaced.  
Participants  who receive  study  vaccine  and subsequently  withdraw,  discontinue,  are terminated 
from the study, or are lost to follow -up will not be replaced.  
6.2.1.2  Participants  Lost to Follow -up 
Any participant  who fails to return  for final assessments  will be contacted  by the site in an 
attempt to have them comply with the protocol.  
All reasonable efforts, including contact of emergency contact, must be made to locate 
participants to determine and report their ongoing status. Lost to follow -up is defined by the 
inability to reach the participant after a minimum of 3 documented remote contacts; eg, phone 
calls, text messages, faxes, or emails (not performed on the same day), as well as a lack of 
response by the participant to one letter that can be tracked to ensure delivery. All attempts 
should be documented in the participant’s source documents and/or medica l records. If it is 
determined that the participant has died, the study site will use permissible local methods to 
obtain  the date and cause  of death  and as much  other  information  as can be obtained,  including 
post-mortem reports.  
The status of participants who fail to complete final assessments will be documented in the 
electronic  case report  form  (eCRF).  Data  that would  have  been  collected  at subsequent  visits  will 
be considered missing.  
6.2.1.3  Study  Vaccination  Pause  Rules  
Study vaccination will be paused in the event of reports of 2 or more events of probable or 
confirmed  pericarditis  or myocarditis  (Table  4), pending  review  of cases  by the Central  Cardiac 
Adjudication Committee that will report the results of their adjudication to the Sponsor to 
recommend whether enrollment may be resumed.  
6.3 Study  Termination  by Sponsor  
Although  the Sponsor  has every  intention  of completing  the study,  it reserves  the right  to 
discontinue it at any time for clinical or administrative reasons.  
The EOS is defined as the date on which the last participant completes the last study visit 
(including  the EOS  visit).  Any additional  long-term follow -up that is required  for monitoring  of 
the resolution of an AE or finding may be appended to the clinical study report (CSR).  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 32 Confidential   
 7 Study  Interventions  
Study vaccinations will comprise 1 intramuscular (IM) injection (Day 1) of 0.5 mL injection 
volume  with a total dose of 5 µg recombinant  rS antigen  with 50 µg Matrix  M adjuvant.  Vaccine 
will be administered as an open -label material.  
 
Vaccine  Baseline 
Serostatus  Number  of 
Doses  Number of 
Participants  Dose  (antigen/ 
Matrix -M 
adjuvant)  
Ancestral  strain  NVX -CoV2373  Previously 
vaccinated  1 100-150 5 μg /  50 μg 
Updated  Novavax  COVID -19 
Vaccine based on recent 
variant(s)  Previously 
vaccinated  1 100-150 5 μg /  50 μg 
7.1 Description  of Products  
7.1.1 NVX -CoV2373  Ancestral  Strain  
7.1.1.1  Formulation,  Storage,  Preparation,  and Handling  
NVX -CoV2373  ancestral  strain  SARS -CoV -2 rS vaccine  will be supplied  as a solution  for 
preparation  for injection  of SARS -CoV -2 rS at a concentration  of 10 μg/mL  and Matrix -M 
adjuvant at a concentration of 100 μg/mL.  
NVX -CoV2373  should  be stored  at 2 to 8°C in a secured  location.  DO NOT  FREEZE.  The study 
site will maintain a temperature log to establish a record of compliance with storage conditions.  
Further  details  on the trial vaccine  can be found  in the SARS -CoV -2 rS IB and  a description  of 
its preparation can be found in the Pharmacy Manual.  
7.1.1.2  Packaging  and Labeling  
The Sponsor  will provide  adequate  quantities  and appropriate  labelling  of SARS -CoV -2 rS with 
Matrix -M adjuvant and Syneos Health will ensure distribution to the study sites from a 
designated depot. The clinical unit pharmacy or equivalent will prepare the clinical trial 
materials. Detailed instructions for the handling of trial vaccine vials will be provided in a 
separate Pharmacy Manual.  
7.1.1.3  Dosing  and Administration  
The vaccine  should  be drawn  into a syringe  on the day of administration  by a qualified  member 
of study site personnel and administered according to standard practice by qualified study site 
personnel as described in the Pharmacy Manual.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 33 Confidential   
 7.1.2 Updated  Novavax  COVID -19 Vaccine  Based  on Recent  Variant(s)  
7.1.2.1  Formulation,  Storage,  Preparation,  and Handling  
The Updated Novavax COVID -19 vaccine will be supplied as a solution for preparation for 
injection  of SARS -CoV -2 rS antigen  at a concentration  of 10 μg/mL  and Matrix -M adjuvant  at a 
concentration of 100 μg/mL.  
The Updated  Novavax  COVID -19 vaccine  should  be stored  at 2 to 8°C in a secured  location.  DO 
NOT FREEZE. The study site will maintain a temperature log to establish a record of 
compliance with storage conditions. Description of its preparation can be found in the Pharmacy 
Manual.  
7.1.2.2  Packaging  and Labeling  
The Sponsor  will provide  adequate  quantities  and appropriate  labelling  of SARS -CoV -2 rS with 
Matrix -M adjuvant and Syneos Health will ensure distribution to the study sites from a 
designated depot. The clinical unit pharmacy or equivalent will prepare the clinical trial 
materials. Detailed instructions for the handling of trial vaccine vials will be provided in a 
separate Pharmacy Manual.  
7.1.2.3  Dosing  and Administration  
The vaccine should be drawn into a syringe on the day of administration by a qualified member 
of study  site personnel,  and the vaccine  should  be administered  according  to standard  practice  by 
qualified study site personnel as described in the Pharmacy Manual.  
7.2 Treatment  Assignment  and Bias Minimization  
7.2.1 Treatment  Allocation  
As this is an open -label trial, a log of the participant ID number with the treatment vial 
administered  will be completed  at the site and will be held by Syneos  Health  during  the study.  
7.2.2 Assessment  and Verification  of Compliance  
Study vaccine should be administered in the clinical unit under direct observation of clinic 
personnel and recorded in the eCRF. The vial number of the vaccine will be recorded for each 
study  participant.  Clinic  personnel  will confirm  that the participant  has received  the entire  dose.  
The location  (right  or left arm, or other  location  if required),  if the full dose was administered, 
date, and timing of all doses of study vaccine will be recorded in the participants’ eCRF. If a 
participant is not administered study vaccine, the  reason for  the missed dose  will be  recorded.  
7.3 Prior  and Concomitant  Therapies  
Administration of medications, therapies, or vaccines will be recorded in the concomitant 
medication eCRF. Prior medications include recent (≤ 90 days) and current medications and 
non-COVID -19 vaccinations.  Concomitant  medications  will include  all medications  (including 
vaccines)  taken  by the participant  from  the time of signing  the ICF through  Day 29 (or through  
the early  termination  visit if prior  to that time).  Prescription  and OTC  drugs  will be included.  Do 
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 34 Confidential   
 not record  herbals,  vitamins,  and supplements.  After  Day 29, concomitant  medications  that may 
have caused or are being used to treat an AE should be recorded.  
Receipt  of all COVID -19 vaccines  prior  to screening  should  be recorded  in the Vaccine  History 
eCRF. Site staff will record the date(s) and brand of the SARS -CoV -2 vaccine received. Any 
COVID -19 vaccine received from Day 30 until EOS should be recorded.  
7.3.1 Prohibited  Therapies  
The following  therapies  are prohibited  within  the specified  timeframes  of study  conduct:  
• Any COVID -19 vaccines  during  the course  of the study.  
• Seasonal  influenza  vaccine  may not be administered  < 4 days before  or < 7 days after the 
study vaccine.  
• All other  vaccines,  except  rabies  vaccine  (if medically  indicated),  ≤ 90 days before 
enrollment until Day 29.  
• Investigational  product  (drug/biologic/device)  from  time of enrollment  until after the last 
study visit.  
• Immunoglobulins, monoclonal antibodies, blood products, or any therapy that causes 
clinically  significant  immunosuppression  within  90 days of study  vaccination  until the 
EOS visit. Similarly, rabies immune globulin should be administered if medically 
indicated.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 35 Confidential   
 8 Safety  assessments  
The timing  and frequency  of all safety assessments  are listed  in the SOE  (Table  1). 
Solicited (reactogenicity) and unsolicited AEs will be graded for severity using the provided 
criteria  (Appendix  3). Recording  of solicited  and unsolicited  AEs will be conducted  by EDC. 
AESIs, including PIMMCs, myocarditis and/or pericarditis (see Table 3 ), and complications 
specific to COVID -19, will also be monitored (see Appendix 2  for details).  
A central Cardiac Adjudication Committee has been established to adjudicate suspected 
myocarditis  and/or  pericarditis  cases  in the clinical  development  plan of NVX -CoV2373. 
Outcomes of the adjudications will be communicated to the Sponsor.  
8.1 Definitions  
• Adverse event – An AE is any untoward medical occurrence associated with the use of 
an intervention in humans whether or not it is considered intervention -related. Any 
abnormal laboratory test results or other safety assessments (eg, physical examination, 
vital signs me asurements) that are clinically significant in the medical and scientific 
judgment  of the investigator  (ie, not related  to progression  of underlying  disease)  will be 
considered AEs. An exacerbation of a chronic or intermittent pre -existing condition, 
including either an increase in frequency and/or intensity, will be considered an AE.  
• Serious  adverse  event  (SAE)  – An event  is considered  “serious”  if, in the view  of either 
the Investigator or Sponsor, it results in any of the following outcomes:  
− Death  
− A life -threatening AE (an event is considered “life -threatening” if, in the view of 
either the investigator or Sponsor, its occurrence places the patient or participant at 
immediate  risk of death.  It does not include  an AE or suspected  adverse  reaction  (AR) 
that, had it occurred in a more severe form, might have caused death.)  
− Inpatient hospitalization or prolongation of existing hospitalization. In general, 
hospitalization signifies that the participant has been detained, usually involving an 
overnight stay, at the hospital or emergency ward for observation and/or treatment 
that would no t have been appropriate in the physician’s office or outpatient setting. 
Hospitalization  for elective  treatment  of a pre-existing  condition  that did not worsen 
from baseline is not considered an SAE.  
− A persistent  or significant  incapacity  or substantial  disruption  of the ability  to conduct 
normal life functions  
− A congenital  anomaly/birth  defect  
− Important medical events that may not result in death, be life -threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical 
judgment, they may jeopardize the patient or participant and may require medical or 
surgic al intervention to prevent one of the outcomes listed in this definition. 
Examples of such medical events include allergic bronchospasm requiring intensive 
treatment in an emergency room (ER) or at home, blood dyscrasias or convulsions 
that do not result  in inpatient  hospitalization,  or the development  of drug dependency 
or drug abuse.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 36 Confidential   
 • Causality or relatedness – For each AE/SAE, the Investigator must document in the 
medical  notes  that he/she  has reviewed  the AE/SAE  and has provided  an assessment  of 
causality as follows.  
− Not Related:  There  is no reasonable  possibility  of relationship  to study  vaccine.  The 
AE does not follow a reasonable temporal sequence from administration of study 
vaccine or can be reasonably explained by the participant’s clinical state or other 
factors (eg, concurrent diseases, and concomitant medications).  
− Related: There is a reasonable possibility of relationship to study vaccine. The AE 
follows a reasonable temporal sequence from administration of study vaccine and 
cannot be reasonably explained by the participant’s clinical state or other factors (eg, 
concurrent diseases or concomitant medications), represents a known reaction to 
study vaccine or other vaccines in its class, is consistent with the known 
pharmacological  properties  of the study  vaccine,  and/or  resolves  with discontinuation 
of the study vaccine (and/or recurs with re -challenge, if applic able).  
• Adverse  reaction – An AR  is any AE caused  by the  investigational  product.  
• Suspected  adverse  reaction  (SAR)  – An SAR  is any AE for which  there  is a reasonable 
possibility that the drug caused the AE. For the purposes of IND safety reporting, 
“reasonable  possibility”  means  there  is evidence  to suggest  a causal  relationship  between 
the drug and the AE. SAR implies a lesser degree of certainty about causality than AR.  
• Unexpected  – An event  is considered  unexpected  if it is not listed  in the IB, is not listed 
at the specificity or severity that has been observed, or, if an IB is not required or 
available, is not consistent with the risk information described in the General 
Investigational Plan or elsewhere in the IND. Unexpected also refers to events tha t are 
mentioned in the IB as occurring with a class of drugs or as anticipated from the 
pharmacological properties of the drug but are not specifically mentioned as occurr ing 
with the particular drug under investigation.  
• Severity or intensity –The severity (or intensity) of an AE/SAE refers to the extent to 
which  it affects  the participant's  daily  activities  and will be classified  as mild,  moderate, 
or severe using the following criteria:  
− Mild:  These  events  require  minimal  or no treatment  and do not interfere  with the 
participant's daily activities.  
− Moderate: These events result in a low level of inconvenience or require minor 
therapeutic  measures.  Moderate  events  may cause  some  interference  with normal 
functioning.  
− Severe: These events interrupt a participant's usual daily activity and may require 
systemic  drug therapy  or other  treatment.  Severe  events  are usually  incapacitating.  
If the severity  of an AE/SAE  changes,  the most  intense  severity  should  be reported.  An 
AE/SAE characterized as intermittent does not require documentation of the onset and 
duration  of each episode.  Grading  criteria  for specific  AEs are provided  in Appendix  2. 
8.1.1 Documenting  Adverse  Events  
At every  study  visit and phone  call, participants  will be asked  to report  any medically  related 
changes in their well -being. They will also be asked if they have been hospitalized, had any  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 37 Confidential   
 accidents, used any new medications that may have caused or were used to treat an adverse 
event,  or changed  concomitant  medication  regimens  (both  prescription  and OTC  medications).  
In addition  to participant  observations,  AEs will be documented  from  any data collected  on the 
AE page of the eCRF or other documents that are relevant to participant safety.  
Care  will be taken  not to introduce  bias when  detecting  AEs,  MAAEs,  and SAEs.  Open -ended 
and non -leading verbal questioning of the participant is the preferred method to enquire about 
AE occurrences. AESIs will be inquired about according to the specific diseases listed in 
Appendix 2.  
When an AE/SAE occurs, it is the responsibility of the investigator to review all available 
documentation  (eg, hospital  progress  notes,  laboratory  reports,  and diagnostics  reports)  related  to 
the event. The investigator will then record all relevant AE/SAE information in the eCRF.  
It is not acceptable for the investigator to send photocopies of the participant’s medical records 
in lieu of completion of the AE/SAE eCRF page. There may be instances when copies of 
medical records for certain cases are requested. In this case, all parti cipant identifiers, with the 
exception  of the participant  number,  will be redacted  on the copies  of the medical  records  before 
submission. The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.  
The following  variables  will be recorded  for each AE: verbatim/AE  description  and date for AE 
start and stop, severity, seriousness, causality, any other action taken, and the outcome. A new 
AE must be recorded if the severity of the AE changes.  
Should an SAE have an outcome of death, the report should contain a comment regarding the 
coinvolvement  of progression  of disease,  if appropriate,  and should  assign  main  and contributory 
causes of death.  
8.1.2 Details  of the Adverse Event  
8.1.2.1  Assessment  of Causality  
There may be situations in which an SAE has occurred and the investigator has minimal 
information to include  in the  initial report. However, it is very important that the Investigator 
always  makes  an assessment  of causality  for every  event  before  the initial  transmission  of the 
SAE data. The Investigator may change their opinion of causality in light of follow -up 
information and send a SAE follow -up report with the updated causality assessment. The 
causality assessment is one of the criteria used when determining regulatory r eporting 
requirements.  
The investigator  should  consider  the following,  before  reaching  a decision  on causality 
assessment:  
• Time  relationship  between  study  vaccine  injection and  event’s  onset.  
• Medical  history.  
• Study treatment.  
• Mechanism  of action of  study vaccine.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 38 Confidential   
 • Class  effect.  
• Concomitant  treatments  in use. 
• Withdrawal  of study  treatment.  
• Lack  of efficacy/worsening  of existing  condition.  
• Possible  vaccine  enhancement  of COVID -19. 
• Erroneous  treatment  with study  medication  or concomitant  medication.  
• Protocol -related  process.  
8.1.2.2  Action  Taken  with Study  Vaccine  due to Adverse Event  
The action  taken  with study  vaccine  should be recorded  using  one of the following:  
• No action  taken  
• Not applicable  
8.1.2.3  Other  Action  Taken  
Details  of any other actions  taken  should  be specified:  
• Specific  therapy/medication  
• Surgical  or medical  procedure  
• Prolonged  hospitalization  
8.1.2.4  AE Outcome  
Each  AE should  be rated  according  to one of the following outcomes:  
• Recovered/resolved  
• Recovering/resolving  
• Not recovered/not  resolved  
• Recovered/resolved  with sequelae  
• Fatal  
• Unknown  
8.1.3 Timeframe  for Collection  
All AEs captured  following  the procedures  listed  in the SOE  (Table  1) will be recorded  on the 
AE page of the eCRF.  
Medical  occurrences  that begin  prior  to administration  of the study  vaccine  will be recorded  on 
the Medical History/Current Medical Conditions section of the eCRF, not the AE section.  
All unsolicited AEs of any severity will be collected from the time of study vaccination through 
28 days after study  vaccination.  After  Day 29, unsolicited  AEs classified  as MAAEs  attributed  to 
study vaccine will be collected until EOS.  
All AESIs/PIMMCs will be collected from the time of study vaccination through EOS. 
All SAEs  will be collected  from  signing  of informed  consent  until completion  of the EOS.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 39 Confidential   
 All vaccine  administration  errors,  MAAEs,  SAEs,  cases  of multisystem  inflammatory  syndrome, 
and hospitalized or fatal cases of COVID -19 following vaccination must be reported based on 
local regulatory reporting guidance for safety events.  
At any time after completion of the EOS visit, if an Investigator learns of an SAE that could 
reasonably  be considered  related  to study  vaccine,  he/she  should  promptly  notify  the Sponsor.  
8.1.4 Classification  of Events  
8.1.4.1  Treatment -Emergent  Adverse  Event  
Treatment -emergent  adverse  events  are defined  as any AE occurring  or worsening  on or after the 
dose of study vaccine.  
8.1.4.2  Adverse  Events  of Special  Interest  
Participants will be assessed for diagnosis of an AESI at all study visits. AESIs include 
PIMMCs, myocarditis or pericarditis, AEs specific  to COVID -19, or  other potential AEs that 
may be determined  at any time by regulatory  authorities  as additional  information  concerning 
COVID -19 is obtained. All AESIs must be reported within 24 hours of site awareness to 
Novavax Global Vaccine Safety on the SAE/AESI form. Listings of AESIs are presented in 
Appendix 2.  
8.1.4.2.1  Myocarditis  and/or  Pericarditis  (CDC  Definition)  
Participants  reporting  signs  or symptoms  of myocarditis  or pericarditis  (fatigue,  acute  chest  pain, 
shortness of breath, etc. (see Table 3 ) within 4 weeks after vaccination should be evaluated as 
soon as possible by a physician who should initiate a diagnostic work up including, but not 
limited to, laboratory tests and initial cardiac evaluation. If probable or confirmed myocarditis 
and/or pericarditis is diagnosed after the initial evaluation, all efforts will be made to route the 
participants to be followed up prefera bly by a cardiologist  who should complete the initial 
evaluation and manage cases following current practice guidelines (eg, AHA or other 
national/local guidelines); this might include performing functional cardiac evaluation and 
follow up of the case unti l resolution (see Table 4 ). A Central Cardiac Adjudication Committee 
has been established to adjudicate possible myocarditis and/or pericarditis cases in the clinical 
development plan of NVX -CoV2373. Outcomes of the adjudications will be communicated to 
the Sponsor.  
All myocarditis  and/or  pericarditis  signs  and symptoms,  as well as all clinical  evaluations,  will 
be considered part of the study record and should be documented in the relevant eCRF pages. 
Participants with confirmed myocarditis or pericarditis will be followed -up to document 
resolution of symptoms and/or abnormal test findings.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 40 Confidential   
 Table 3  Case  Definitions  of Probable  and Confirmed  Myocarditis,  Pericarditis,  and 
Myopericarditis  
 
Condition  CDC  Definition  
 PROBABLE:  
 Presence  of ≥ 1 new  or worsening  of the following  clinical symptoms:1  
 • Chest  pain,  pressure,  or discomfort  
• Dyspnea,  shortness  of breath,  or pain with breathing  
• Palpitations  
• Syncope 
AND  
 ≥ 1 new  finding of 
 
 
 
 
 
 
 
Acute 
myocarditis  • Troponin  level  above  upper  limit of  normal  (any type  of troponin)  
• Abnormal  ECG  or rhythm  monitoring  findings  consistent  with 
myocarditis2  
• Abnormal  cardiac  function  or wall motion  abnormalities  on 
echocardiogram  
• cMRI  findings  consistent  with myocarditis3 
AND  
• No other  identifiable cause  of the symptoms  and findings  
CONFIRMED:  
Presence  of ≥ 1 new  or worsening  of the following  clinical symptoms:1  
 • Chest  pain,  pressure,  or discomfort  
• Dyspnea,  shortness  of breath,  or pain with breathing  
• Palpitations  
• Syncope 
AND  
 ≥ 1 new  finding of 
 • Histopathologic  confirmation  of myocarditis4  
• cMRI findings consistent with myocarditis3 in the presence of 
troponin  level  above  upper  limit  of normal  (any type of troponin)  
AND  
• No other  identifiable cause  of the symptoms  and findings  
Acute 
pericarditis5  Presence  of ≥ 2 new  or worsening  of the following  clinical features:  
• Acute  chest  pain6  
• Pericardial  rub on exam  
• New  ST-elevation  or PR-depression  on ECG  
• New  or worsening  pericardial  effusion  on echocardiogram  or MRI 
Myopericarditis  This term may be used for patients  who meet  criteria  for both myocarditis 
and pericarditis.  
Abbreviations:  AV = atrioventricular;  CDC  = Centers  for Disease  Control  and Prevention;  cMRI  = cardiac  magnetic 
resonance imaging; ECG = electrocardiogram; ESC = European Society of Cardiology; MRI = magnetic 
resonance imaging.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 41 Confidential   
 1. Persons  who lack the listed  symptoms  but who meet  other  criteria  may be classified  as subclinical  myocarditis 
(probable or confirmed).  
2. Using  the Dallas  criteria  [Aretz  1987 ]. Autopsy  cases  may be classified  as confirmed  clinical  myocarditis  on the 
basis of meeting histopathologic criteria if no other identifiable cause.  
3. To meet  the ECG  or rhythm  monitoring  criterion,  a probable  case must  include  at least one of 1) ST-segment  or 
T-wave abnormalities; 2) Paroxysmal or sustained atrial, supraventricular,  or ventricular  arrhythmias; or  3) AV 
nodal conduction delays or intraventricular conduction defects.  
4. Using  either  the original  or the revised  Lake  Louise  criteria  [Ferreira  2018 ]. 
5. Based  on the 2015  ESC Guidelines  for the diagnosis  and management  of pericardial  diseases  [Adler  2015 ]. 
6. Typically  described  as pain made  worse  by lying  down,  deep  inspiration,  or cough,  and relieved  by sitting  up or 
leaning forward, although other types of chest pain might occur.  
Adapted  from  Gargano  2021.  
 
 
Table 4  Management  of Suspected  Myocarditis,  Pericarditis,  and Myopericarditis 
Cases  
 
Clinical  Presentation  Procedures  
 
 
 
 
 
 
Probable  or Confirmed 
Myocarditis, 
Pericarditis or 
Myopericarditis  1) ER visit and evaluation  by a physician  (as per national/local  guidelines):  
a. Diagnostic  work  up might  include:  
i. CBC,  Inflammatory  markers:  ESR,  CRP 
ii. Cardiac  markers:  Troponin  I, BNP,  NT-proBNP  
iii. Chest  radiograph  
iv. ECG  
2) Evaluation  by a cardiologist/pediatric  cardiologist  (as applicable)  
a. Follow  AHA  or other  national/local  guidelines  
i. Diagnostic  work  might  include:  
1. Stress  test echocardiogram  
2. Cardiac  biopsy  
3. cMRI  
4. Other  laboratory  or cardiac  assessment  tests as 
applicable  
Follow  up until resolution  
Abbreviations: AHA = American Heart Association; BNP =  brain natriuretic peptide; CBC = complete blood count; cMRI = 
cardiac  magnetic  resonance  imaging;  CRP  = C-reactive  protein;  ECG  = electrocardiogram;  ER = emergency  room;  ESR 
= erythrocyte  sedimentation  rate; NT-proBNP  = N-terminal  pro b -type natriuretic  peptide.  
 
8.1.4.2.2  Electrocardiograms  
All participants will undergo a baseline ECG at Day 1 prior to study vaccine administration. 
Baseline  ECGs  will be read and interpreted  by a Central  Cardiac  Adjudication  Committee  only 
as a comparison with new ECG(s) in the event that the participant experiences a cardiac event 
that constitutes a possible case of myocarditis and/or pericarditis at any time during the study 
that requires review by the Cardiac Adjudication Committee.  
8.1.4.3  Medically  Attended  Adverse  Events  
An MAAE  is defined  as an AE that leads  to an unscheduled  visit to a healthcare  practitioner.  All 
MAAEs will be reported from the time of study vaccination through Day 29.  After Day 29, 
MAAEs attributed to study vaccine will be captured until EOS.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 42 Confidential   
 8.1.4.4  Reactogenicity  Symptoms  
On the day of  vaccination, participants will remain in clinic  (or under  observation)  for at least 
15 minutes  to be observed  for any immediate  reaction.  Injection  site specific  local  and general 
systemic reactogenicity reactions including start and stop dates will be recorded following 
vaccination. Any immediate reaction will be recorded as an AE on day of vaccination.  
Participants will utilize  their diary to record reactogenicity for  the 7 days following vaccination. 
All participants will record reactogenicity starting on the same day of the vaccination and for a 
total of 7 days.  Should  any reactogenicity  event  extend  beyond  7 days after vaccination  (toxicity 
Grade ≥ 1), then it will be recorded as an AE with a start date that matches Day 8 of the 
reactogenicity  event  and followed  to resolution  per FDA  guidelines  for AE capture.  The toxicity 
grading scale implemented in the diary is included in Appendix 3 . 
8.2 Reporting  Adverse  Events  
All SAEs  must  be reported  according  to ICH Good  Clinical  Practice  (GCP)  or local  regulations, 
applying the regulation with the stricter requirements. Investigators and other study site 
personnel must inform the appropriate Novavax representatives of any SAE that occurs during 
the course of the study, from the time of informed consent u ntil the EOS visit, regardless of 
whether it is judged to be causally related to study vaccine or procedures. Notification must 
occur  within  24 hours  of when  they become  aware  of it. AESIs,  including  PIMMC,  myocarditis 
or pericarditis and AESIs related to COVID -19 are to be reported within these timelines. The 
investigator should make every effort to obtain follow -up information on the outcome until the 
event is considered resolved, chronic and/or stable.  
SAE reporting forms allow for the notation of other factors that may have impacted the 
investigator’s  assessment  of causality.  Investigators  will be instructed  to utilize  this section  of the 
reporting form to note the impact of an approved/authorized vaccine from a different 
manufacturer on the event, if applicable. Investigators will be required to report any SAEs in 
participants who received a different manufacturer’s approved/authorized  vaccine to local health 
care and/or regulatory authorities as per the local regulatory guidelines.  
If a non-serious  AE becomes  serious,  this and other  relevant  follow -up information  must  also be 
provided  to Novavax Global  Vaccine  Safety  within  24 hours  as described  above.  The date when 
the AE becomes serious should be notated in the eCRF and on the SAE form.  
All SAEs and AESIs will also be recorded in the eCRF and the paper SAE/AESI form. The 
investigator  is responsible  for informing  the Institutional  Review  Board  (IRB)  of the SAE  as per 
local requirements.  
Paper  SAE  forms  should  be completed  at the study  site, signed  (physically  or electronically)  by 
the Investigator or a qualified Sub-Investigator and emailed within 24 hours of study site 
awareness of the event to the Novavax Global Vaccine Safety mailbox:  
Safety@novavax.com  
The SAE  form  should  be attached  to the email;  a notification  email  of the event  describing  it in 
the email text is not sufficient. There may be situations when an SAE has occurred, and the 
investigator has minimal information to include in the initial SAE report. However, it is very  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 43 Confidential   
 important  that the investigator  always  makes  an assessment  of causality  for every  event  prior  to 
transmission of the SAE report form.  
Minimum  criteria  for a reportable  event  are: 
• Identifiable  patient  (participant  number)  
• A suspect  product  (ie, study  vaccine)  
• An identifiable  reporting  source  (investigator/study  site identification),  and 
• An event  or outcome  that can be identified  as serious.  
Follow -up information  on SAEs  must  also be reported  by the investigator  within  the same  time 
frames.  
8.2.1.1  Safety  Reporting  to Health  Authorities,  Independent  Ethics  Committees/ 
Institutional Review Boards, and Investigators  
Novavax  or its designee will  be responsible  for notifications  of SAEs  and other  qualifying  events 
that are considered to be unexpected and related to study vaccine as expedited (eg, 7 - or 15 -Day 
reports) to the relevant regulatory authorities and to participating investigators. In addition, 
Novavax or its designee will follow all applicable loca l and national regulatory requirements 
regarding safety reporting. Each investigator must comply with any applicable study local and 
national  regulatory  requirements  related  to the reporting  of SAEs  to the IRB/IECs  responsible  for 
reviewing the trial at their site, as well as the regulatory authority(ies) (where applicable).  
Timelines  and responsibilities  (Novavax  and its designee)  for expedited  and periodic  safety 
reporting to the Health Authorities, Independent Ethics Committees/ Institutional Review 
Boards, and Investigators are provided in the Safety Management Plan as agreed by CRO 
designee and Novavax.  
8.3 Pregnancy  
Pregnancy is not considered an AE unless there is a suspicion that an investigational vaccine 
may have interfered with the effectiveness of a contraceptive medication. Any pregnancy that 
occurs during study participation must be reported using the Pregnanc y reporting form. To 
ensure participant safety, each pregnancy must be reported to Novavax Global Vaccine Safety 
within  24 hours  of learning  of its occurrence.  Each  pregnancy  must  be followed  up to determine 
outcome (including spontaneous miscarriage, elec tive termination, normal birth, or congenital 
abnormality) and the status of both mother and child, even if the participant was discontinued 
from the study. Pregnancy complications and elective terminations for medical reasons must be 
reported as an AE or SAE. Spontaneous miscarriages must be reported as an SAE.  
Any pregnancy brought to the Investigator’s attention before the study completion or  after the 
participant  has completed  the study  but occurring  while  the participant  was enrolled  in the study 
must be promptly reported to Novavax Global Vaccine Safety: Safety@novavax.com  using the 
pregnancy reporting forms provided to the sites.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 44 Confidential   
 8.4 Overdose  
A drug overdose is defined as the accidental or intentional use of a drug or medicine or an 
administration error in an amount that is higher than is normally used. Every overdose must be 
reported to Novavax Global Vaccine Safety within 24 hours of awarenes s, using the details 
provided  in Section  9.3 if the overdose  was associated  with an SAE.  Other  overdoses  and those 
associated with non -serious AEs should be reported in the eCRF AE page. Only overdoses 
associated with a clinical SAE  need to be  reported as an SAE. The  quantity and duration of  the 
excess dose should be documented in the eCRF.  
Overdose  in this study  is specifically  defined  as any dose greater  than the intended  protocol  dose 
(Section 7.1.1.3 ). In case of overdose, it is recommended that the participant be monitored for 
any signs  or symptoms  of adverse  reactions  or effects  and appropriate  symptomatic  treatment  be 
administered immediately. Note that administration of the “wrong” vaccine is a protocol 
deviation, but not, in the absence of associated AE, an SAE.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 45 Confidential   
 9 Analysis  
This section  includes  a description  of the statistical  strategy  and considerations  for the study. 
Further detailed specifications for the analysis of data from the study will be presented in a 
Statistical Analysis Plan.  
9.1 Sample  Size Rationale  
The sample size and power are driven by the primary endpoint (ie, Nab responses to ancestral 
strain  Novavax  vaccine  administered  as a second  (or subsequent)  booster  after licensed  mRNA 
vaccines and a first ancestral strain Novavax vaccine booster).  
MN50  data from  Novavax’s  Study  2019nCoV -301 of around  240 adult  participants  who received 
the SARS -CoV -2 rS vaccine on Day 0 and Day 21 in the initial period of primary series or 
crossover period then received boost dose at Day 0 in the booster period exhibited an 80% 
confidence upper bound of standard deviation of MN50 GMFR between 28  days after the third 
active (booster) dose and 14 days after 2nd active dose in log10 scale of 0.61.  
The sample size (Table 5 ) is based on providing at least 90% power to conclude non -inferiority 
on Nab titers  given  the null hypothesis  of GMFR  (GMTDay29 -312/GMTD29 -307) ≤ 0.67.  Here, 
GMTDay29 -312 is Nab GMT  at Day 29 from  2019nCoV -312 and GMTDay29 -307 is Nab GMT 
at Day 29 from Study 307. It is anticipated that these estimates will be equally applicable in the 
event that a different assay of Nab titers is used for this study.  
 
Table  5 Summary  of Sample  Size 
GMFR  N 
1.0 129 
1.1 85 
1.2 62 
1.3 49 
1.4 40 
1.5 34 
Abbreviation:  GMFR=geometric  mean  fold rise; N=number  
9.2 Analysis  Subsets  
The following  analysis  sets are identified  for analysis.  
9.2.1 Selected  Participants  Analysis  Set 
The Selected Participants Analysis Set will include all participants who are enrolled, regardless 
of whether  they actually  received  any study  vaccine.  The Selected  Participants  Analysis  Set will 
be used for participant  disposition  summaries  and will be analyzed  according  to the treatment  as 
enrolled.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 46 Confidential   
 9.2.2 Full Analysis  Set 
The full analysis set (FAS) will include all participants who are enrolled and received a dose of 
study vaccine, regardless of protocol violations or missing data. Participants in the FAS will be 
analyzed  according  to the vaccine  group  as enrolled.  Immunogenicity  summaries  and associated 
statistical analyses will be based primarily on the PP Analysis Set and may also be analyzed in 
the FAS.  
9.2.3 Safety  Analysis  Set 
The Safety Analysis Set will include all participants who receive a dose of study vaccine. 
Participants  in the Safety  Analysis  Set will be analyzed  as actually  treated.  The Safety  Analysis 
set will be used for all safety analyses.  
9.2.4 Per-Protocol  Analysis  Set 
The PP Analysis Set will include all participants who receive the study vaccine according to the 
protocol,  have  serology  results  for Day 1 and Day 29 available  after the vaccination,  and have  no 
major protocol violations that are considered clinically relevant to impact immunogenicity 
response as determined by Novavax prior to database lock.  
The analysis  of the primary  endpoint  will be performed  using  the PP Analysis  Set. 
Within  the PP Analysis  Set there  are 3 subsets  defined:  Anti-S Protein  IgG Serology  Subset, 
Neutralization Assay Subset, and the hACE2 Receptor -binding Inhibition Assay Subset.  
9.2.4.1  Anti-S Protein  IgG Serology  Subset  
All participants  in the PP Analysis  Set who are tested  for anti-S protein  IgG serology  using 
ELISA prior to study vaccination will be included in this subset.  
9.2.4.2  Neutralization  Assay  Subset  
All participants  in the PP Analysis  Set who are tested  for neutralization  prior  to study 
vaccination will be included in this subset.  
9.2.4.3  hACE2  Receptor -Binding  Inhibition  Assay  Subset  
All participants  in the PP Analysis  Set who are tested  for ACE2  receptor -binding  inhibition  prior 
to study vaccination will be included in this subset.  
9.3 Statistical  Analyses  
9.3.1 Background  Analyses  
9.3.1.1  Disposition  and Protocol  Compliance  
The number  of participants  consented,  enrolled,  and vaccinated  will be presented  by the study 
vaccine group for the Selected Participants Analysis Set.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 47 Confidential   
 The number (percentage) of participants in the Selected Participants Analysis Set, FAS, Safety 
Analysis  Set, and PP Analysis  Set who have  completed  the study  (from  Day 1 through  Day 181) 
will be summarized by the study vaccine group.  
The number (percentage) of participants in the Safety Analysis Set who discontinue the study 
prior  to EOS  and the reason  for discontinuation  (eg, AE, investigator  decision,  lost to follow -up, 
non-compliance) will be presented by the study vaccine group. A listing of all participants 
discontinued from the study will be presented, including the reason for discontinuation and day 
of last study contact. Day of last study contact will be calculated as follows: date of study 
discontinuation minus date of Day 1 vaccination +1.  
The number (percentage) of participants in the Safety Analysis Set with major protocol 
deviations recorded throughout the study will be summarized by study vaccine group and 
protocol  deviation  category  (Section  11.1.3 ). A listing  of all participants  with one or more  major 
protocol deviations will also be provided and will include study vaccine group, study day 
associated  with the deviation  relative  to Day 1, protocol  deviation  category,  and a description  of 
the deviation as recorded by the site.  
9.3.1.2  Demographics  and Baseline  Characteristics  
Baseline demographic and background characteristics (eg, age, sex, ethnicity, race, height, 
weight,  body  mass  index  [BMI,  derived  will be summarized  by the study  vaccine  group  for the 
FAS, Safety Analysis Set, and PP Analysis Set. Frequencies and percentages will be presented 
for categorical variables. Continuous variables will be summarized using descriptive statistics 
(total  number  of participants,  mean  and standard  deviation,  median,  minimum,  and maximum).  
Medical history will be coded using Medical Dictionary for Regulatory Activities (MedDRA) 
terms. Baseline medical history recorded at Screening will be summarized by the study vaccine 
group  and by MedDRA System  Organ  Class/Preferred  Term  (SOC/PT)  for all  participants  in the 
Safety  Analysis  Set. Within  each SOC  and PT, the number  and percentage  of participants  with at 
least one medical history event will be presented, respectively. Multiple events within a given 
SOC and PT for a participant will be counted once.  
The time between  last dose of previous  COVID -19 vaccination  and Day 1 vaccination  dose may 
be summarized for the study vaccine group(s) using descriptive statistics.  
9.3.2 Immunogenicity  Analyses  
The immunogenicity  analysis  will be performed  using  the PP Analysis  Set. 
For the primary  endpoint  of Nab responses  to the ancestral  strain  Novavax  vaccine  administered 
as a second (or subsequent) booster after licensed mRNA vaccines and a first ancestral strain 
Novavax vaccine booster, Nab GMTs at Day 1 and Day 29 will be summarized for the group 
receiving the ancestral strain Novavax vaccine. Nab GMTs along with the corresponding 2 -sided 
95% CIs, are calculated by exponentiating the corresponding log -transformed means and their 95% 
CIs. GMFR  is defined as the ratio of Nab  titers within the group of ancestral strain Novavax 
vaccine between two different time -points (Day 29 vs. Day 1) to be conducted using t 
distribution on the log -transformed ratio. Ratio of Nab GMTs for the group receiving the 
ancestral strain Novavax vaccine between 28 days post first dose (a t Day 29) in Study  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 48 Confidential   
 2019nCoV -312 and 28 days post first dose (at Day 29) in Study  307 among  the same  participants 
will be conducted using t distribution on the log -transformed ratio to evaluate non -inferiority.  
Non-inferiority  will be demonstrated  if the LB of the 95% CIs for the ratio of Nab GMT at  Day 
29 between  the two booster  periods  is > 0.67.  If non-inferiority  is demonstrated,  results  will be 
tested  for superiority, defined  as the LB of 95% CIs for the ratio of Nab GMTs  at Day 29 > 1.0. 
For the secondary endpoint of Nab responses to ancestral strain Novavax vaccine administered  
as a second (or subsequent) booster after licensed mRNA vaccines and a first ancestral strain 
Novavax vaccine booster, the proportion of participants in the group receiving ancestral strain 
Novavax vaccine who achieve seroconversion ( ≥ 4-fold increase from baseline) in Nab titers to 
the SARS -CoV -2 at Day 29 defined as SCR will be calculated. SCR in Nab titers with 
corresponding 2 -sided exact binomial 95% CIs will be  calculated using the Clopper -Pearson 
method. Two -sided 95% CIs of the difference of SCRs in Nab titers for the group receiving the 
ancestral strain Novavax vaccine between 28 days post first dose (at Day 29) in Study 
2019nCoV -312 and 28 days post first dose (at Day 29) in Study  307 among  the same  participants 
will be based on the method of confidence interval (CI) for the difference in two correlated 
proportions by Tango (the method of Tango CIs will be described in the Statistical Analysis 
Plan). Non -inferiority will be demonstrated if the LB of the 95% exact CIs for the difference of 
SCRs in Nab titers is higher than –10%.  
For the secondary endpoints of noninferior immunogenicity of the Novavax vaccine as a second 
(or subsequent) booster vs as a first booster of ancestral strain Novavax vaccine boost following 
mRNA  vaccines,  IgG geometric  mean  enzyme -linked  immunoassay  (ELISA)  unit concentrations 
(GMEU/mL) to the SARS -CoV -2 ancestral strain spike protein for the group receiving ancestral 
strain Novavax vaccine at Day 1 and Day 29 will be calculated. IgG GMEU along with the 
corresponding 2 -sided 95% CIs is calculated by exponentiating the corresponding log - 
transformed means and their 95% CIs. GMFR is defined as the ratio of IgG GMEUs withi n the 
group receiving the ancestral strain Novavax vaccine; An analysis of the study vaccine group 
between two different time -points (Day 29 vs. Day 1) will be conducted using t distribution on 
the log -transformed ratio. The ratio of IgG GMEUs for the grou p receiving the ancestral strain 
Novavax vaccine between 28 days post first dose (at Day 29) in Study 2019nCoV -312 and 28 
days post first dose (at Day 29) in Study 307 among the same participants will be conducted 
using t distribution on the log -transforme d ratio to evaluate non -inferiority. Non -inferiority will 
be demonstrated if the lower -bound (LB) of the 95% CIs for the ratio of IgG GMEU at Day 29 
among the same participants between the two booster periods is higher than 0.67. If non - 
inferiority is dem onstrated, results will be tested for superiority, defined as a lower 95% CI for 
the ratio of IgG GMEUs at Day 29 > 1.0. The proportion of participants in the group receiving 
the ancestral strain Novavax vaccine who achieve seroconversion ( ≥ 4-fold increase from 
baseline) in IgG concentrations to the SARS -CoV -2 ancestral strain spike protein at Day 29 is 
defined as the SCR. SCR in IgG GMEUs with corresponding two -sided exact binomial 95% CIs 
will be calculated using the Clopper -Pearson method.  Two-sided 95%  CIs of the difference of 
SCRs in IgG GMEUs for the group receiving the ancestral strain Novavax vaccine between 28 
days post first dose (at Day 29) in Study 2019nCoV -312 and 28 days post first dose (at Day 29) 
in Study 307 among the same participants will  be calculated using the method of CI for the  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 49 Confidential   
 difference  in two correlated  proportions  by Tango.  Non inferiority  will be demonstrated  if the 
LB of the 95% exact CIs for the difference of SCRs in IgG GMEUs is higher than –10%.  
For the secondary endpoints of cross -reaction of neutralizing and IgG antibodies induced by the 
ancestral strain Novavax vaccine to more recent SARS -CoV -2 variants for which appropriate 
assays are available, post -booster neutralizing GMTs, IgG GMEU, and GM FR for the group 
receiving  updated  NVX -CoV2373  based  on recent  variant(s)  will be obtained  using  the methods 
noted above. Ratio of Nab GMT, difference of SCRs in Nab titers, ratio of IgG GMEUs, and 
differences  in SCRs  in IgG GMEUs  for the group receiving  the updated  NVX -CoV2373  vaccine 
based on recent variant(s) is to be calculated among the same participants from Study 307.  
For the secondary  endpoints  of antibody  responses  in a human  angiotensin -converting  enzyme  2 
(hACE2)  receptor binding inhibition assay to the SARS -CoV -2 ancestral strain spike protein, 
the same statistical methods applied for the analysis of Nabs will be applied to hACE2,b 
including GMT, ratio of GMT, SCR, and difference in SCRs for the group receiving an cestral 
strain Novavax vaccine.  
For the exploratory objective of utilizing additional assays (current or to be developed) to best 
characterize the immune response for future vaccine development needs, including testing 
against  emerging  variants  of SARS -CoV -2, the same  statistical  methods  applied  for Nab,  IgG or 
hACE2 may be applied to evaluate immune responses based on the assays used.  
9.3.3 Safety  Analyses  
To describe the overall safety of ancestral strain and updated (if administered) Novavax 
vaccine(s)  administered  as a second  (or subsequent)  booster  following  licensed  mRNA  vaccines 
and a first ancestral strain Novavax vaccine booster, the secondary endpoints of safety data 
include solicited AEs in the 7 days following study vaccination and MAAEs, AESIs (including 
myocarditis and/or pericarditis), and SAEs throughout the study. All safety analyses will be 
descriptive and conducted using the Safety Analysis Set.  
All local/systemic  solicited  (reactogenicity)  AEs within  the post-vaccination  window  (Days  1-7) 
by the verbatim terms, and by severity (mild, moderate, severe) using the maximal severity 
observed for the specific symptom post -vaccination will be summarized for each study vaccine 
group.  
Unsolicited MAAEs, AESIs (including myocarditis and/or pericarditis), and SAEs throughout 
the study will be summarized by the study vaccine group and by SOC and PT using MedDRA 
terms, as well as by severity and relationship to the study vaccine to present the number and 
percentage with its corresponding exact 95% CIs using Clopper -Pearson method. For multiple 
occurrences  of an AE in the same  participant,  a participant  will be counted  only once  within  an 
SOC or a PT, using the most severe occurrence and clos est reported relationship for the 
summarization by severity or relationship to the study vaccine, respectively. The duration of 
MAAEs, AESIs, and SAEs through Day 181 will also be summarized.  
A by-participant  listing  of MAAEs,  AESIs,  and SAEs  throughout  the study  will also be 
provided.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 50 Confidential   
 9.3.3.1  Prior  and Concomitant  Medications  and Vaccinations  
Prior  and concomitant  medications  and vaccinations  will be summarized  by study  vaccine  group 
and preferred drug name as coded using the WHO drug dictionary for all participants in the 
Safety Analysis Set. Multiple occurrences of medication usage for a participant will be counted 
only once within an anatomical therapeutic chemical (ATC) term and standardized medication 
name.  A by-participant  listing  of prior  and concomitant  medications  (including  vaccines)  will be 
presented.  
9.3.3.2  Vital  Sign Measurements  
Vital  sign measurements  including  temperature,  respiratory  rate, blood  pressure,  and pulse  rate 
will be summarized as continuous variables.  A by -participant listing of vital signs will be 
provided.  
9.3.3.3  Physical  Examinations  
Physical  examination  at Screening  or Day 1 will include  height  and weight,  cervical  and axillary 
lymph nodes, and heart, and any other areas based on participant symptoms. A targeted 
examination will be performed at unscheduled visits.  
9.4 Interim  Analyses  
The 1st interim analysis will be performed when the complete data for Nab titers and/or IgG 
GMEUs  and/or  hACE2  titers  for the ancestral  strain  Novavax  vaccine  and safety  data from  Day 
1 through Day 29 are available.  
The 2nd interim  analysis  will be performed  when  the complete  data for Nab titers  and/or  IgG 
GMEUs and/or hACE2 titers for an updated Novavax vaccine are available.  
The first and second  interim  analysis  may be combined  into one analysis  depending  on when  the 
ancestral strain arm of the study and the updated Novavax vaccine arm are executed.  
9.5 Final  Analysis  
The final analysis  will be performed  when  safety  data throughout  the study  (from  Day 1 through 
EOS) are available.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 51 Confidential   
 10 Ethical  Considerations  
10.1 Good  Clinical  Practice  
The investigator agrees that the study will be conducted according to the principles of ICH 
E6(R2). The investigator will conduct all aspects of this study in accordance with all national, 
state,  and local  laws or regulations.  The study  will be conducted  in compliance  with the protocol, 
current GCP guidelines – adopting the principles of the Declaration of Helsinki – and all 
applicable regulatory requirements.  
Prior  to study  initiation,  the protocol  and the informed  consent  documents  will be reviewed  and 
approved  by the sponsor  (or designee)  and an appropriate  ethics  committee.  Any amendment  to 
the protocol or  consent materials must also be  approved by the  study sponsor  (or designee)  and 
IRB and must be submitted/notified to the regulatory authority, as required, before they are 
implemented.  
10.2 Ethics  Review  
Prior  to the start of the study,  the investigator  is responsible  for ensuring  that the protocol  and 
consent form have been reviewed and approved by a relevant IRB. The IRB shall be 
appropriately constituted and perform its functions in accordance with ICH GCP and local 
requirements as applicable.  
The IRB shall  approve  all protocol  amendments  (except  for logistical  or administrative  changes), 
written informed consent documents and document updates, participant recruitment procedures 
(eg, advertisements), written information to be provided to the participants, IB, available safety 
information, information about payment and compensation  available to participants, the 
investigator's curriculum vitae and/or other evidence of qualifications and any other documents 
requested by the IRB and Regulatory Autho rity (Competent Authority) as applicable.  
10.3 Informed  Consent  
The nature  and purpose  of the study  shall  be fully  explained  to each participant.  They  must  be 
informed that participation is voluntary.  
Documentation of informed consent (either written or via eConsent) must be obtained from each 
participant prior to any study procedures being performed. The process of obtaining informed 
consent must be documented in the participant’s source documents. The authorized person 
obtaining the informed consent must also sign the ICF, and a copy of the ICF must be provided 
to the participant.  Participants  must  be re-consented  to the most  current  version  of the ICF during 
their participation in the study.  
Participants will be requested to provide the name and contact information for an emergency 
contact and to provide consent for future testing to support establishment of correlates of 
protection  against  SARS -CoV -2 infection  and disease  (see Section  regarding  sample  retention).  
The consent documents to be used for the study shall include all the elements of informed 
consent  as outlined  in accordance  with ICH GCP  and local  requirements  as applicable  and be 
reviewed and approved by the appropriate IRB prior to use.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 52 Confidential   
 10.4 Data  Privacy  
All laboratory specimens, evaluation forms, reports, and other records will be identified in a 
manner designed to maintain participant confidentiality. All records will be kept in a secure 
storage area with limited access. Clinical information will not be released without the written 
permission  of the participant,  except  as necessary  for monitoring  and auditing  by the sponsor,  its 
designee, relevant regulatory authority(ies), or the IRB.  
The investigator and all employees and co -workers involved with this study may not disclose or 
use for any purpose other than performance of the study, any data, record, or other unpublished, 
confidential  information  disclosed  to those  individuals  for the purpose  of the study.  Prior  written 
agreement from the sponsor or its designee must be obtained for the disclosure of any said 
confidential information to other parties.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 53 Confidential   
 11 Oversight  
11.1 Quality  Control  and Assurance  
The Sponsor/designee shall implement and maintain quality control and quality assurance 
procedures with written standard operating procedures (SOPs) to ensure that the study is 
conducted  and data are generated,  documented,  and reported  in compliance  with the protocol, 
ICH GCP, and applicable regulatory requirements.  
This study  shall  be conducted  in accordance  with the provisions  of the Declaration  of Helsinki 
(October 2013) and ICH GCP (CPMP/ICH/135/95 and updates).  
The investigator  will be responsible  for the following:  
• Providing written summaries of the status of the study to the IRB annually or more 
frequently  in accordance  with the requirements,  policies,  and procedures  established  by 
the IRB.  
• Notifying  the IRB of SAEs  or other  significant  safety  findings  as required  by IRB 
procedures.  
The investigator  may not deviate  from  the protocol  without  a formal  protocol  amendment  having 
been established and approved by an IRB, except when necessary to eliminate immediate 
hazards to the participant or when the change(s) involve(s) only logistical or administrative 
aspects of the study. Any deviations may result in the participant ha ving to be withdrawn from 
the study and render that participant non -evaluable.  
The identification and reporting of serious breaches of ICH GCP or the protocol to the 
Regulatory  Authorities  and Ethics  Committees  will be conducted  according  to local  SOPs  and 
regulations.  
11.1.1  Monitoring  
The Syneos  Health  clinical  monitor,  as a representative  of the sponsor,  is obligated  to follow  the 
study closely. In doing so, the monitor will visit the investigator and study site at periodic 
intervals in addition to maintaining necessary telephone and email contact. The monitor will 
maintain current personal knowledge of the study through observa tion, review of study records 
and source documentation, and discussion of the conduct of the study with the investigator and 
personnel.  
All aspects  of the study  will be carefully  monitored  by the sponsor  or its designee  for compliance 
with applicable government regulation with respect to current ICH E6(R2) guidelines and 
standard operating procedures.  
11.1.2  Audits  
The investigator and institution involved in the study will permit study -related monitoring, 
audits,  IRB review,  and regulatory  inspections  by providing  direct  access  to all study  records.  In 
the event of an audit, the investigator agrees to allow the sponsor, their representatives, or the 
regulatory authority access to all study records.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 54 Confidential   
 The investigator  should  promptly  notify  the sponsor  of any audits  scheduled  by any regulatory 
authorities and promptly forward copies of any audit reports received to the sponsor.  
11.1.3  Protocol  Deviations  
The investigator or designee must document and explain in the participant’s source 
documentation any deviation from the approved protocol. The investigator may implement a 
deviation from, or a change to, the protocol to eliminate an immediate hazard to stu dy 
participants without prior IRB approval. As soon as possible after such an occurrence, the 
implemented deviation or change, the reasons for it, and any proposed protocol amendments 
should  be submitted  to the IRB for review  and approval,  to the sponsor  for agreement,  and to the 
regulatory authorities, if required.  
A protocol  deviation  is any change,  divergence,  or departure  from  the study  design  or procedures 
defined in the protocol. An important deviation (sometimes referred to as a major or significant 
deviation) is a subset of protocol deviations that leads to a participant being discontinued from 
the study or significantly affects the participant ’s rights, safety, or well -being and/or the 
completeness, accuracy, and reliability of the study data. An important deviation can include 
nonadherence  to inclusion  or exclusion  criteria  or nonadherence  to regulatory  authority  including 
ICH E6(R2) guidelines.  
Protocol deviations will be documented by the clinical monitor throughout the course of 
monitoring  visits.  The investigator  will be notified  in writing  by the monitor  of deviations.  The 
IRB should be notified of all protocol deviations, as appropriate, in a timely manner.  
Review  and categorization  of protocol  deviations  will occur  prospectively  during  the study  prior 
to database lock(s).  
11.1.4  Records  
11.1.4.1  Data  Capture  and Management  
All required study data will be entered by study site personnel in the eCRF or by study 
participants  in the paper  diary  created  for the study.  Data  required  according  to this protocol  will 
be recorded by study site personnel via data entry into the internet -based EDC software system 
or by study participant via the paper diary. The investigator shall ensure that all data from 
participant visits are promptly entered into the eCRFs in acco rdance with the specific 
instructions given. The investigator must sign each eCRF to verify the integrity of the data 
recorded. All internal Syneos Health and external study site personnel seeking access to the 
eCRF are supported by a Service Desk (if applicable). At the end of the study all data captured 
electronically will b e provided to the investigator on CD ROM for archiving at the study site.  
The Sponsor  or designee  is responsible  for the data management  of this study  including  quality 
checking of the data.  
11.1.4.2  Source  Documentation  
The investigator must maintain source documents, such as laboratory reports, consultation 
reports,  reactogenicity  diaries  and complete  medical  history  and physical  examination  reports. 
All information in the CRF must be traceable to the participant’s source documents.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 55 Confidential   
 The investigator/institution  shall  provide  direct  access  to source  data/documents  for study  related 
monitoring, audits, IRB review, and regulatory inspection.  
11.1.4.3  Records  Retention  
The investigator/institution should maintain the study documents as specified in the ICH 
guidelines on GCP and as required by the applicable regulatory requirements. The 
investigator/institution  should  take measures  to prevent  accidental  or premature  destruction  of 
these documents.  
It is the Sponsor’s  responsibility  to inform  the investigator/institution  as to when  these 
documents no longer need to be retained.  
11.2 Study  Termination  or Study  Site Closure  
Although  the sponsor  has every  intention  of completing  the study,  they reserve  the right  to 
discontinue it at any time for clinical or administrative reasons.  
The end of the study is defined as the date on which the last participant completes the last study 
visit (including  the EOS  visit and any additional  long-term follow -up). Any additional  long-term 
follow -up that is required for monitoring of the resolution of an AE or finding may be appended 
to the clinical study report.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 56 Confidential   
 12 Publication  Policy  
The Sponsor  shall  retain  the ownership  of all data.  When  the study  is complete  the Sponsor  shall 
arrange the analysis and tabulation of data. A clinical study report shall then be prepared, which 
may be used for publication, presentation at scientific meetings or submission to regulatory 
authorities.  
The Sponsor  will generally  support  publication  of multicenter  studies  only in their entirety  and 
not as individual study site data. In this case, a coordinating investigator will be designated by 
mutual agreement. Authorship will be determined by mutual agreement and in line with the 
International Committee of Medical Journal Editors authorship agreements. Authors will be 
provided  reasonable  access  to all study  data,  statistical  tables,  figures, and  relevant  reports  and 
will have  the opportunity  to review  complete  study  results.  All proposed  publications  based  on 
this study must be participant to the Sponsor's approval requirements.  
The Sponsor assures that the key design elements of this protocol will be posted in a publicly 
accessible  database  such as clinicaltrials.gov.  In addition,  upon  study  completion  and finalization 
of the study report, the results of this trial will be submitted for publication and/or posted in a 
publicly accessible database of clinical trial results.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 57 Confidential   
 13 Financing  and Insurance  
The investigator is required to provide financial disclosure information to allow the sponsor to 
submit the complete and accurate certification or disclosure statements required under US Title 
21 CFR Part 54 and local regulations. In addition, the investig ator must provide to the sponsor a 
commitment  to promptly  update  this information  if any relevant  changes  occur  during  the course 
of the investigation and for 1 year following the completion of the study.  
Neither the sponsor nor Syneos Health nor the study site is financially responsible for further 
testing  or treatment  of any medical  condition  that may be detected  during  the screening  process. 
In addition, in the absence of specific arrangements, neither the sponsor nor Syneos Health nor 
the study site is financially responsible for further treatment of the disease under study.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 58 Confidential   
 14 References  
Adler  2015  
Adler Y, Charron P, Imazio M, et al, for the ESC Scientific Document Group. 2015 ESC 
Guidelines  for the diagnosis  and management  of pericardial  diseases:  The Task  Force  for the 
Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology 
(ESC) Endorsed by: The European Association for Cardio -Thoracic Surgery (EACTS), Eur 
Heart J .2015; 36 (42): 2921 –2964.  
Aretz  1987  
Aretz  HT, Billingham  ME, Edwards  WD,  et al. Myocarditis.  A histopathologic  definition  and 
classification. Am J Cardiovasc Pathol 1987; 1:3 –14). 
CDC  2021  
Centers for Disease Control and Prevention. SARS -CoV -2 Variant Classifications and 
Definitions.  Available  at: https:// www.cdc.gov/coronavirus/2019 -ncov/variants/variant - 
info.html#Interest. Accessed on October 06, 2021.  
DAIDS  2017  
Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), 
National  Institutes  of Health  (NIH),  US Department  of Health  and Human  Services.  Division  of 
AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. July 2017. 
Available at: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf.  
DaSilva  2013  
DaSilva FT, DeKeyser FD, Lambert P -H, et al. Optimal approaches to data collection and 
analysis  of potential  immune  mediated  disorders  in clinical  trials  of new vaccines.  Vaccine. 
2013;31:1870 -1876.  
DHHS 2007  
U.S. Department of Health and Human Services. Food and Drug Administration, Center for 
Biologics Evaluation and Research (US). Guidance for industry: Toxicity grading scale for 
healthy  adult  and adolescent  volunteers  enrolled  in preventive  vaccine  clinical  trials.  September 
2007. Available at: https://www.fda.gov/media/73679/download  
Ferreira  2018  
Ferreira  VM, Schulz -Menger  J, Holmvang  G,et al. Cardiovascular  magnetic  resonance  in 
nonischemic myocardial inflammation: Expert recommendations. J Amer Coll 
Cardiol.2018;72(24): 3158 -3176.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 59 Confidential   
 Gargano  2021  
Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID -19 vaccine after reports of 
myocarditis  among  vaccine  recipients:  Update  from  the Advisory  Committee  on Immunization 
Practices — United States, June 2021. MMWR Morb Mortal Wkly Rep 2021;70:977 –982. 
Habibzadeh  2020  
Habibzadeh  P, Stoneman  EK. The novel  coronavirus:  a bird’s  eye view.  Int J Occup  Environ 
Med. 2020;11(2):65 -71. 
Lambert  2020  
Lambert  P-H, Ambrosino  DM, Andersen  SR, et al. Consensus  summary  report  for CEPI/BC 
March 12 -13, 2020 meeting: Assessment of risk of disease enhancement with COVID -19 
vaccines. Vaccine. 2020;38(31):4783 -4791.  
Law  2021  
Law YM, Lal AK, Chen S, et al. Diagnosis and management of myocarditis in children: a 
scientific  statement  from  the American  Heart  Association.  Circulation.  2021;144:e123 –e135.  
Novavax  2022  
Clinical  Investigator’s  Brochure  for SARS -CoV -2 Recombinant  Spike  Protein  Nanoparticle 
Vaccine (SARS -CoV -2 rS). Novavax, 2022.  
Su 2016  
Su S, Wong  G, Shi W, et al. Epidemiology,  genetic  recombination,  and pathogenesis  of 
coronaviruses. Trends Microbiol. 2016;24(6):490 -502. 
WHO 2022  
World Health Organization (WHO). Coronavirus disease (COVID -19) pandemic. Available at: 
https:// www.who.int/emergencies/diseases/novel -coronavirus -2019.  Accessed  10 February  2022.  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 60 Confidential   
 Appendix  1 PROTOCOL  CHANGE  HISTORY  
 
Protocol  Version  2.1, 26 March 2025  (revised  from  Version  2.0, 23 February  2023 ) 
The following  is a summary of  changes  made  to the protocol.  
 
Location  of Change  Change/Modification  in Version  2.1, 26 March 2025  
Title Page  Administrative Change – Added the NCT  to Clinical Trial Registry 
Identifiers  
 
Protocol  Version  2.0, 23 February  2023  (revised  from  Version  1.0, February  10, 2023)  
The following  is a summary of  changes  made  to the protocol.  
 
Location  of Change  Change/Modification  in Version  2.0, 23 February  2023  
Schedule  of Events  Superscripted  “1” on the Screening  Day to correct  error  
Schedule  of Events 
and Section 7.3  Changed  “caused”  to “may  have  caused”  to description  of concomitant 
medications to be recorded for consistency.  
Figure  1 Removed  “phone  call”  from  flow diagram  (Figure 1). 
Schedule  of Events 
footnote and 
throughout the 
document  Changed  “Memory Aid” to  diary  for greater accuracy.  
Table  7 Updated  to another  version  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 61 Confidential   
 Appendix  2 LISTINGS  OF ADVERSE  EVENTS  OF SPECIAL  INTEREST  
Because  it has been  hypothesized  that immunizations  with or without  adjuvant  may be associated 
with autoimmunity, regulatory authorities have requested that Novavax instruct investigators to 
be especially vigilant regarding the PIMMC listed below (Table 6 ). Note that this regulatory 
request is not specific to Novavax’s SARS -CoV -2 rS or Matrix -M adjuvant; and there is no 
current  evidence  to suggest  that the study  vaccines  in this protocol  are, or are not, associated  with 
these illnesses. The list is not intended to be exhaustive, nor does it exclude the possibility that 
other diagnoses may be AESI.  
 
Table  6 Potential  Immune -Mediated  Medical  Conditions  
Categories  Diagnoses  (as MedDRA  Preferred  Terms)  
Neuroinflammatory  Disorders:  Acute  disseminated  encephalomyelitis  (including  site-specific  variants: 
eg, non -infectious encephalitis, encephalomyelitis, myelitis, 
myeloradiculomyelitis), cranial nerve disorders including 
paralyses/paresis (eg, Bell’s palsy), generalized convulsion, Guillain - 
Barre  syndrome  (including  Miller  Fisher  syndrome  and other  variants), 
immune -mediated peripheral  neuropathies and plexopathies (including 
chronic  inflammatory  demyelinating  polyneuropathy,  multifocal  motor 
neuropathy and polyneuropathies associated with monoclonal 
gammopathy), myasthenia gravis, multiple sclerosis, narcolepsy, optic 
neuritis, transverse myelitis, uveitis.  
Musculoskeletal  and Connective 
Tissue Disorders:  Antisynthetase syndrome, dermatomyositis, juvenile chronic arthritis 
(including Still’s disease), mixed connective tissue disorder, 
polymyalgia  rheumatic,  polymyositis,  psoriatic  arthropathy,  relapsing 
polychondritis, rheumatoid arthritis, scleroderma (including diffuse 
systemic form and CREST syndrome), spondyloarthritis (including 
ankylosing spondylitis, reactive arthritis [Reiter's Syndrome] and 
undifferentiated spondyloarthritis), systemic lupus erythematosus, 
systemic sclerosis, Sjogren’s syndrome.  
Vasculitis  Large  vessels  vasculitis  (including  giant  cell arteritis  such as Takayasu's 
arteritis and temporal arteritis), medium sized and/or small vessels 
vasculitis (including polyarteritis nodosa, Kawasaki's disease, 
microscopic polyangiitis, Wegener's granulomatosis, Churg –Strauss 
syndrome [allergic granulomatous angiitis], Bu erger’s disease 
[thromboangiitis obliterans], necrotizing vasculitis and ANCA -positive 
vasculitis [type unspecified], Henoch -Schonlein purpura, Behcet's 
syndrome, leukocytoclastic vasculitis).  
Gastrointestinal  Disorders:  Crohn’s  disease,  celiac  disease,  ulcerative  colitis,  ulcerative  proctitis.  
Hepatic  Disorders:  Autoimmune  hepatitis,  autoimmune  cholangitis,  primary  sclerosing 
cholangitis, primary biliary cirrhosis.  
Renal  Disorders:  Autoimmune glomerulonephritis (including IgA nephropathy, 
glomerulonephritis rapidly progressive, membranous 
glomerulonephritis,  membranoproliferative  glomerulonephritis,  and 
mesangioproliferative glomerulonephritis).  
Cardiac  Disorders:  Autoimmune  myocarditis/cardiomyopathy.  
Myocarditis  and/or  pericarditis  
Skin Disorders  Alopecia  areata,  psoriasis,  vitiligo,  Raynaud’s  phenomenon,  erythema 
nodosum, autoimmune bullous skin diseases (including pemphigus,  
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 62 Confidential   
  
Table  6 Potential  Immune -Mediated  Medical  Conditions  
Categories  Diagnoses  (as MedDRA  Preferred  Terms)  
 pemphigoid and dermatitis herpetiformis), cutaneous lupus 
erythematosus,  morphoea,  lichen  planus,  Stevens -Johnson  syndrome, 
Sweet’s syndrome.  
Hematologic  Disorders:  Autoimmune  hemolytic  anemia,  autoimmune  thrombocytopenia, 
antiphospholipid syndrome, thrombocytopenia.  
Metabolic  Disorders:  Autoimmune thyroiditis, Grave’s or Basedow’s disease, new onset 
Hashimoto  thyroiditis a, diabetes  mellitus  type 1, Addison’s  disease.  
Other  Disorders:  Goodpasture  syndrome,  idiopathic  pulmonary  fibrosis,  pernicious 
anemia, sarcoidosis.  
Abbreviations:  ANCA  = anti-neutrophil  cytoplasmic  antibody;  IgA = immunoglobulin  A; MedDRA  = Medical 
Dictionary for Regulatory Activities.  
DaSilva  2013  
Complications  specific  to COVID -19 are listed  below  (Table  7). The list is not intended  to be 
exhaustive, nor does it exclude the possibility that other diagnoses may be AESI.  
Table  7 Adverse  Events  Representing  Complications  Specific  to COVID -191 
 
Categories  Diagnoses  (as MedDRA  System  Organ  Class/Preferred  Term)  
Respiratory/Infectious  Disorders:  ARDS,  pneumonitis,  septic  shock -like syndrome.  
Cardiac  Disorders:  Acute  cardiac  injury,  arrhythmia.  
Coagulopathy  Deep  vein thrombosis,  myocardial  infarction,  stroke.  
Renal  Disorders:  Acute  kidney  injury.  
Hematologic  Disorder  Thrombocytopenia,  septic  shock -like syndrome.  
Inflammatory  Disorders:  Cytokine  Release  Syndrome  related  to COVID -19 infection2, multisystem 
inflammatory syndrome in children (MIS -C). 
Neurologic  Disorders:  Generalized  convulsions  
Abbreviations:  ARDS  = acute  respiratory  distress  syndrome;  COVID -19 = coronavirus  disease  2019;  DAIDS  = 
Division of AIDS; MedDRA = Medical Dictionary for Regulatory Activities.  
1 COVID -19 manifestations  associated  with more  severe  presentation  and decompensation  with consideration  of 
enhanced  disease  potential.  The current  listing  is based  on Coalition  for Epidemic  Preparedness  Innovations  
/Brighton  Collaboration  Consensus  Meeting  (12/13  March  2020)  and expected  to evolve  as evidence 
accumulates (Lambert 2020 ). 
2 Cytokine  release  syndrome  related  to COVID -19 infection  is a disorder  characterized  by nausea,  headache, 
tachycardia, hypotension, rash, and/or shortness of breath (DAIDS 2017 ). 
Clinical  Study  Protocol 
2019nCoV -312 
Version  2.0 SARS -CoV -2 rS Vaccine  
COVID -19 
Novavax,  Inc. 63 Confidential   
  
APPENDIX 3  TOXICITY  GRADING  SCALE  FOR  CLINICAL  ABNORMALITIES, 
(LOCAL AND GENERAL SYSTEMIC REACTOGENICITY, 
CLINICAL LABORATORY, AND VITAL SIGNS)  
Table  8 FDA  Toxicity  Grading  Scale  for Local  and General  Systemic  Reactogenicity  
 
Local  Reaction  to Injectable  Product  
Clinical 
Abnormality  Mild 
(Grade  1)  
Moderate  (Grade  2) Severe 
(Grade  3) Potentially Life 
Threatening  (Grade  4) 
Pain Does  not interfere 
with activity  Repeated use  of non- 
prescription pain 
reliever  > 24 hours  or 
interferes with 
activity  Any use of narcotic  
pain reliever  or prevents 
daily activity  ER visit  or hospitalization  
Tenderness  Mild  discomfort  to 
touch  Discomfort  with 
movement  Significant  discomfort 
at rest  ER visit  or hospitalization  
Erythema/rednessa 2.5 − 5 cm 5.1 − 10 cm > 10 cm For all participants:  Necrosis 
or exfoliative dermatitis  
Induration/swellingb 2.5 − 5 cm and 
does not interfere  
with activity  5.1 − 10 cm or 
interferes  with 
activity  > 10 cm or prevents 
daily activity  For all participants:  Necrosis  
Systemic  (General)  
 Mild 
(Grade  1)  
Moderate  (Grade  2) Severe 
(Grade  3) Potentially Life 
Threatening  (Grade  4) 
Feverc 
(°C)c (°F) 38.0 − 38.4 
100.4  − 101.1  38.5 − 38.9 
101.2  − 102.0  39.0 − 40 
102.1  − 104 > 40 
> 104 
Nausea/vomiting  No interference 
with activity  or 
1 − 2 episodes/24  h 
ours Some  interference 
with activity or  
> 2 episodes/24  hours  Prevents  daily  activity, 
or requires outpatient 
IV hydration  Requires  ER visit or 
hospitalization for 
hypotensive shock  
Headache  No interference 
with activity  Repeated  use of non- 
narcotic  pain reliever  
> 24 hours or 
interferes  with 
activity  Significant; any use of 
narcotic  pain reliever  or 
prevents daily activity  ER visit  or hospitalization  
Fatigue/Malaise  No interference 
with activity  Some  interference 
with activity  Significant,  prevents 
daily activity  ER visit  or hospitalization  
Myalgia  No interference 
with activity  Some  interference 
with activity  Significant,  prevents 
daily activity  ER visit  or hospitalization  
Arthralgia  No interference 
with activity  Some  interference 
with activity  Significant,  prevents 
daily activity  ER visit  or hospitalization  
Abbreviations:  DHHS  = Department  of Health  and Human  Services;  ER = emergency  room;  FDA  = United  States  Food  and 
Drug Administration.  
a In addition  to grading  the measured  local  reaction  at the greatest  single  diameter,  the measurement  should  be recorded  as a 
continuous  variable.  
b Induration/swelling  should  be evaluated  and graded  using  the functional  scale  as well as the actual  measurement.  
c Oral temperature;  no recent  hot or cold beverages. 
Source: [ DHHS 2007 ]. 